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ABSTRACT  
 
Background: Early detection of individuals who are at risk of developing Glucose Intolerance 
would decrease the morbidity and mortality associated with this disease. MicroRNA is one of 
the most widely studied biomolecules involved in epigenetic mechanisms, hence it offers 
unique opportunities in this regard. Circulating microRNAs are associated with disease 
pathogenesis during the asymptomatic stage of disease. This has therefore attracted a lot of 
attention as a potential biomarker for identifying individuals who have an increased risk of 
developing Glucose Intolerance. The identification of high risk biomarkers for Glucose 
Intolerance will go a long way to eliminate the possible complications that arise due to late 
diagnosis and treatment of Glucose Intolerance. This could ultimately lead to better ways to 
prevent, manage and control the Glucose Intolerance epidemic that is rampant worldwide. The 
aim of the study is to investigate expression of circulating microRNA’s in blood of mixed 
ancestry subjects with glucose intolerance.  
Methods: A quantitative cross-sectional study design involving 36 individuals [who were age, 
gender and BMI (Body Mass Index) matched] from a total population of 1989 participants of 
mixed ancestry descent, residing in Bellville South, South Africa was used. Participants were 
classified as controls (normoglycemic), pre-diabetic (preDM) and diabetic (DM) (screen 
detected diabetic) according to WHO criteria of 1998. MicroRNAs were extracted from serum 
using the Qiagen miRNeasy Serum/Plasma Kit (ThermoFisher). The purified micro RNAs were 
reverse-transcribed to cDNA (complementary deoxyribonucleic acid) using the Qiagen RT2 
First Strand Kit. Then, using Qiagen miScript SYBR Green PCR kit and miScript miRNA PCR 
arrays (ThermoFisher), the real time polymerase chain reaction was done to determine the 
expression profile the circulating micro RNAs present in the serum of the participants.  
Results: The 36 participants were evenly divided into 3 groups of 12 participants each as 
mentioned earlier. There were significant differences between groups in the waist (cm) 
(p=0.0415) and waist/hip ratio (p=0.0011) with highest values in the DM group and lowest in 
the normal group. Clinical parameters varied significantly according to glycemic status. As 
expected, the FBG (mmol/L) (p<0.0001), 2 HRs Post Glucose (mmol/L) (p<0.0001), HbA1c 
(%) (p=0.0009), Fasting Insulin (mIU/L) (p=0.0039), were all highest in the DM and lowest in 
the control group. In contrast, the 2 HRs Post Insulin (mIU/L) (p = 0.0027) was highest in the 
preDM group and lowest in the normal group, while the Glucose/Insulin ratio (p=0.0477) was 
highest in the normal group and lowest in the preDM group. Triglycerides (mmol/L) (p=0.0043) 
and Total Chol (mmol/L) (p=0.0429) were significantly increased through the three groups, 
with highest values in the DM group and lowest in the normal group. Furthermore, 12 of the 84 
miRNAs studied were expressed through all the 3 groups and they exhibited both inverse and 
positive correlations between the clinical parameters, especially the glucose parameters 
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(Fasting blood glucose, 2 hours post glucose, Fasting blood insulin, 2 hours post insulin and 
Glycated Hemoglobin).  
Discussion: The expression of circulating micro RNAs varied amongst the controls, preDM 
and DM groups. The observation of circulating micro RNAs changes in preDM, the 
asymptomatic stage of T2DM (Type 2 Diabetes Mellitus), and the identification of more 
pronounced changes in individuals with diabetes suggests that these epigenetic changes could 
be involved in the progression of T2DM, and holds potential as biomarkers for T2DM.  
Conclusion: Our results add to the growing body of evidence that circulating miRNAs are 
associated with glucose intolerance and can be detected during pre-DM, the asymptomatic 
stage of T2DM and in T2DM as well. These findings support the use of miRNAs as biomarkers 
for early detection of T2DM. To our knowledge, this is the first study to assess circulating 
miRNAs in serum as biomarkers for glucose intolerance in the mixed ancestry population in 
South Africa and paves the way for future studies in Africa at large. 
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DEFINITIONS  
 
 Biomarker: a naturally occurring molecule, gene or characteristic by which a particular 
pathological or physiological process or disease can be identified.  
 Diabetes: a condition whereby a person’s blood glucose levels are higher than normal 
and above threshold value 
 Pre-diabetes: a condition whereby a person’s blood glucose levels are higher than 
normal but not high enough to be classified as diabetic. The condition includes IGT and 
IFG. 
 Dysglycemia: abnormality in blood sugar stability 
 Hyperglycemia: increase in blood glucose level above normal 
 Epigenetics: heritable changes in gene function which do not involve nucleotide 
sequence changes.  
 Epigenome: the overall epigenetic state of an organism.  
 Genome: the overall gene collection of an organism.  
 microRNA: miRNAs are short noncoding RNAs 
 Down-regulation is the process by which a cell decreases the quantity of a cellular 
component, such as RNA or protein.  
 Up-regulation is the process by which a cell increases the quantity of a cellular 
component, such as RNA or protein. 
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CHAPTER 1: LITERATURE REVIEW  
 
1.1 Glucose intolerance  
Glucose intolerance is an umbrella term for metabolic conditions which results in higher than 
normal blood glucose levels “hyperglycemia” (WHO, 2006). Conditions which can be 
considered as glucose intolerance include: Impaired fasting glucose (IFG), Impaired glucose 
tolerance (IGT), pre-diabetes (preDM) and Types 1 and 2 diabetes mellitus (T1DM and T2DM) 
(WHO, 2006). Other forms include gestational diabetes and maturity onset diabetes of the 
young (MODY) (Keating and El-Osta, 2013). Diabetes mellitus (DM) is the sixth leading cause 
of death worldwide with diabetic sufferers having twice the risk of death than someone of the 
same age without diabetes (WHO, 2014). More than half a million children aged 14 and under 
are living with T1DM (International Diabetes Federation “IDF”, 2015). Furthermore, it is 
estimated that 415 million adults aged 20-79 now have DM worldwide, including 193 million 
who are undiagnosed (IDF, 2015). A further 318 million adults are estimated to have impaired 
glucose tolerance which puts them at risk of developing T2DM (IDF, 2015). Statistically, if this 
rise is not halted, by 2040 there will be 642 million people living with DM (IDF, 2015). Moreover, 
DM is the second leading cause of death in South Africa and the first leading cause of death 
in the Western Cape, with the mixed ancestry population showing the second highest 
prevalence of diabetes after the Indian population (Erasmus et al., 2012). DM was reported to 
be significantly increased, hence identified as the number one killer in the Western Cape South 
Africa (IDF, 2015). 
 
1.2. Diabetes mellitus 
 
DM is a major cause of morbidity and mortality worldwide. The three most common forms are; 
T1DM, T2DM and gestational diabetes (GDM), accounting for approximately 5 %, 90 % and 3 
% of all DM cases, respectively (ADA, 2010; ADA, 2014).  
 
1.2.1. Type 1 Diabetes (T1DM)  
Type 1 diabetes, also referred to as insulin dependent diabetes mellitus (IDDM) or juvenile 
diabetes, is an autoimmune disorder characterized by hyperglycemia due to the inability of the 
pancreas to secrete insulin (ADA, 2017). It is a diabetes mellitus with early onset, and is due 
to T-cell mediated autoimmune destruction of beta cells (β-cell) resulting in insulin deficiency 
and hyperglycemia. Exogenous administration of insulin, usually by injection, and recently via 
an insulin pump, is required to maintain normoglycemia (Afrand et al., 2012; ADA, 2017). 
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Furthermore, an insulin patch has been developed for the treatment of T1DM. The insulin patch 
is an artificial pancreas modeled device, which is fully automated, closed-loop and has the 
ability to monitor insulin levels without the patient’s input (Anhalt and Bohannon, 2010; ADA, 
2017). Although the majority of T1DM cases occur due to autoimmunity, in some cases, the 
disease arises spontaneously with no definite cause (Seino et al., 2010). In certain cases, 
latent autoimmune diabetes of adults (LADA), also known as type 1.5 diabetes is an adult 
onset autoimmune diabetes which shares features of both T1DM and T2DM (Afrand et al., 
2012). LADA is often misdiagnosed as T2DM because physicians base their diagnosis on 
patient age rather than on aetiology (Afrand et al., 2012). Although clinical dilemma exists in 
initial diagnosis, early diagnosis and interventions can influence the speed of progression 
towards insulin dependency (Fourlanos et al., 2006). 
1.2.2. Gestational diabetes mellitus  
 
Gestational diabetes mellitus (GDM) is first diagnosed during pregnancy (Seino et al., 2010). 
The mechanisms underlying GDM are not yet fully elucidated, although progressive insulin 
resistance during pregnancy has been implicated. About 20 - 50 % of women with GDM 
develop T2DM later in life (Afrand et al., 2012). Although transient in nature, GDM can 
adversely affect the health of the fetus and mother. Risks to the baby include macrosomia 
(high birth weight), congenital cardiac and nervous system abnormalities, skeletal muscle 
malformations and increased fetal insulin levels, which inhibit fetal surfactant production, 
possibly resulting in respiratory distress syndrome. In severe cases, perinatal death may occur, 
most commonly as a result of poor placental perfusion due to vascular system impairment 
(Afrand et al., 2012).  
1.2.3. Other types of diabetes  
 
Other forms of DM include monogenic forms such as neonatal diabetes and  MODY, diabetes 
of the exocrine pancreas such as cystic fibrosis related diabetes, and drug induced or chemical 
induced diabetes such as steroid diabetes induced by high doses of glucocorticoids (Aguiree 
et al., 2013; ADA, 2015). These forms of diabetes are rare and collectively account for less 
than 5 % of all diabetes cases (Bloomgarden, 2004 & ADA, 2015).  
 
1.2.4. Type 2 diabetes 
1.2.4.1. Epidemiology in South Africa  
 
T2DM is the major contributor to the DM epidemic accounting for more than 90 % of DM cases 
globally (ADA, 2014). South Africa is one of the 32 countries with high numbers of diabetic 
cases, with 2.28 million cases of diabetes recorded (IDF, 2015). Gwebu reported that about 
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3.5 million South Africans (6 % of the population) have T2DM, while about 5 million South 
Africans have pre-diabetes, (Gwebu, 2013). Pre-diabetes precedes T2DM with about 5 - 10 % 
people with pre-diabetes usually progressing to DM annually (Forouhi et al., 2007; Nathan et 
al., 2007). A prevalence survey conducted between 2008 - 2009 in the Bellville South 
community, in the Western Cape province of South Africa, reported an age-adjusted T2DM 
prevalence of 26.3 % in individuals of mixed ethnic ancestry in this setting (Erasmus et al., 
2012). A study conducted in the Cape Town suburbs of Langa, Gugulethu, Crossroads, 
Nyanga and Khayelitsha between 2008 and 2009 reported a prevalence of 13.1 % in black 
South Africans which is almost half of that reported for individuals of mixed ethnic ancestry in 
the Bellville South setting during the same period (Erasmus et al., 2012; Peer et al., 2012). 
1.2.4.2. Aetiology 
 
The aetiology of T2DM involves both environmental and genetic factors (Tripathy and Chavez, 
2010). Studies have reported that only about 5 - 10 % of T2DM cases can be explained by 
genetics (Voight et al., 2010). Thus environmental factors have received increased attention 
as major mediators of T2DM progression (Barrès et al., 2009; Hirst and Marra, 2009; Drong et 
al., 2012; Keating and El-Osta, 2013). In most cases a diabetogenic lifestyle and a susceptible 
genotype is required for disease development. A diabetogenic lifestyle includes excessive 
caloric intake, inadequate caloric expenditure such as physical inactivity and obesity (Nolan et 
al., 2011). 
1.2.4.3. Pathophysiology 
 
 T2DM is characterized by hyperglycaemia due to defects in insulin action in peripheral tissues, 
specifically skeletal muscle, liver, adipocytes and brain as well as decreased insulin secretion 
due to pancreatic β-cell dysfunction (Fernandez-Valverde et al., 2011; Tripathy and Chavez, 
2010). Moreover, the pathogenesis of T2DM involves a combination of genetic and 
environmental/lifestyle factors (Tripathy and Chavez, 2010). Compared with healthy 
individuals, subjects with impaired glucose tolerance have a 50% to 70% decline in β-cell 
function, T2DM sets in when 80 to 90% of β-cell function decline (Ward et al., 2003; Gastaldelli 
et al., 2004; Ferrannini et al., 2008). The hormone insulin is the primary mediator of glucose 
homeostasis (Leahy, 2005). After the ingestion of food, β-cells in the pancreas secrete insulin 
to increase glucose uptake in insulin-responsive tissues such as skeletal muscle and 
adipocytes, and to decrease glucose production from the liver so as to restore normoglycemia. 
However, insulin resistance, defined as the condition where insulin responsive tissues fail to 
increase glucose uptake in response to physiological concentrations of insulin leads to 
persistent hyperglycemia (Reaven, 2005; Yarbrough et al., 1998). Insulin resistance is 
characterized by high levels of circulating insulin, due to increased insulin secretion by β-cells 
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as a compensatory mechanism to counteract insulin resistance. A number of factors including 
insulin resistance, as described above, genetic predisposition, glucotoxicity, lipotoxicity, 
increased reactive oxygen species (ROS), endoplasmic reticulum (ER) stress and elevated 
intracellular calcium contribute to β-cell dysfunction, which is a prerequisite for the 
development of T2DM (Tripathy and Chavez, 2010; Cerf, 2013).  
Although the exact mechanisms underlying the development of T2DM is not yet completely 
understood, insulin resistance in peripheral tissue, and decreased insulin secretion due to 
pancreatic β-cell dysfunction is accepted to play a major role (Tripathy and Chavez, 2010). 
Initially β-cells compensate for insulin resistance by increasing insulin secretion, however they 
subsequently become exhausted and dysfunctional (Poitout and Robertson, 2008). In severe 
cases of T2DM, β-cells are unable to secrete insulin, requiring the administration of exogenous 
insulin. T2DM pathophysiology is thought to commence about 10 years prior to clinical 
diagnosis, at which time insulin resistance is high and β-cell function is already significantly 
impaired. Moreover, T2DM related microvascular and macrovascular complications are 
thought to occur about 5 to 10 years before diagnosis (Tripathy and Chavez, 2010).  
Lifestyle factors and genetic predispositions leading to insulin resistance account for the 
glycemic changes from normoglycemia, IGT and finally to DM (Tripathy and Chavez, 2010). 
This study is aimed to show that epigenetics also has a major role to play in dysglycemia, by 
displaying the role of circulating miRNAs as biomarkers for this disease process (Kato et al., 
2013). 
1.2.4.4. Complications of diabetes 
 
Microvascular complications of diabetes include diabetic retinopathy, neuropathy and 
nephropathy (Afrand et al., 2012). Diabetic retinopathy affects blood vessel formation in the 
retina of the eye, and can lead to reduced vision and blindness (Afrand et al., 2012). Diabetic 
neuropathy is the result of the impact of diabetes on the nervous system, most commonly 
causing numbness, tingling and pain in the feet, and also increases the risk of skin damage 
due to altered sensation (Afrand et al., 2012). Diabetic nephropathy, due to the impact of 
diabetes on the kidneys, may lead to scarring in kidney tissue, loss of small and progressively 
larger amounts of protein in the urine, and eventually chronic kidney disease requiring dialysis 
(Donaghue et al., 2009). In conjunction with vascular disease in the legs, neuropathy 
contributes to the risk of diabetes-related foot ailments, such as diabetic foot ulcers, which are 
difficult to treat and usually require amputation (Afrand et al., 2012; Aguiree et al., 2013). The 
major long-term macrovascular complications associated with DM relate to blood vessel 
damage, with DM doubling the risk of cardiovascular disease.  
Cardiovascular disease is the most common cause of death and disability in diabetic patients 
(Aguiree et al., 2013). The main macrovascular diseases (related to atherosclerosis of larger 
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arteries) in diabetes are ischemic heart disease (angina and myocardial infarction), stroke and 
peripheral vascular disease. Capillary damage may also occur, causing macro and 
microangiopathy (Boussageon et al., 2011). Macroangiopathy refers to an angiopathy (blood 
vessel disease), which affects large and medium size blood vessels (Boussageon et al., 2011). 
Microangiopathy refers to an angiopathy that affects small blood vessels in the body 
(Boussageon et al., 2011).  
One of the major diabetes complications during T1DM and the late stages of T2DM is diabetic 
ketoacidosis (DKA). Diabetic ketoacidosis is defined as a state of high anion gap metabolic 
acidosis due to an excessive concentration of ketone bodies (keto-anions) in the bloodstream 
(Kitabchi et al., 2009). Due to the body’s inability to utilize glucose as an energy source in 
these individuals, fat is metabolized as an alternative source of energy. Fat or lipid metabolism 
produces ketone bodies as by-products. Ketone bodies (acetoacetate, beta-hydroxybutyrate 
and acetone) are released into the bloodstream where they dissociate into ketone anions and 
hydrogen ions (H+). In an attempt to maintain extracellular pH and ionic balance, H+ ions are 
coupled with bicarbonate ions (HCO3-), which depletes the body’s alkali reserves. The end 
result is acidosis and failure to regulate the ionic balance, which can result in fatal 
consequences such as a coma or even death (Fowler, 2009; Kitabchi et al., 2009).  
The respiratory system tries to compensate for acidosis by increasing the rate of breathing in 
order to exhale more carbon dioxide resulting in rapid deep breathing with a smell of acetone 
known as Kussmaul breathing (Fowler, 2009; Kitabchi et al., 2009). Other symptoms include 
nausea, vomiting, abdominal pain and an altered state of consciousness (Ali et al., 2012). The 
fatality of the complication emanates from the fact that it can occur acutely as an initial 
manifestation of T1DM with no history of the disease manifestation or diagnosis. 
An acute attack may also result from an increased insulin requirement in known T1DM patients 
and sometimes T2DM patients. Hyperglycemic hyperosmolar state (HHS) also known as 
hyperosmolar non-ketotic state is another less common, but equally fatal complication of T2DM 
(Afrand et al., 2012; Brenner, 2006). The disorder is characterized by reduced lipolysis 
(breakdown of triglycerides into glycerol and fatty acids) and ketoacidosis. Hyperglycemic 
hyperosmolar state has a slower onset than DKA and is characterized by markedly high 
hyperglycemia, hyperosmolality and severe dehydration (Afrand et al., 2012; Brenner, 2006).  
1.2.4.5. Current methods of diagnosis  
 
In 1979, the National Diabetes Data Group (NDDG) issued the first unified classification of 
diabetes (NDDG, 1979). This was followed by the World Health Organization’s (WHO) 
classification in 1980 (WHO, 1980). These two recommendations ushered a more 
standardized approach to the diagnosis of diabetes (Alberti and Zimmet, 1998). The WHO 
criterion was modified in 1985, and again in 1998 (Alberti and Zimmet, 1998; WHO, 1999). 
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The latest recommendations worldwide are based on the 2006 WHO recommendations (WHO, 
2006) modified in 2011 to include glycated haemoglobin type A1c (HbA1c) (WHO, 2011) and 
the American Diabetes Association (ADA) criteria of 2014 modified in 2016 to include HbA1c 
(ADA, 2014; ADA, 2016), as seen in the table below. 
 
Table 1.1: WHO and ADA Diagnostic Criteria (Adapted from WHO, 2006; ADA, 2010; 
WHO, 2011)  
 
Footnotes 
 The FPG test = measures blood glucose concentrations after an overnight fast (about 
eight hours without food but may have water). Individuals with IFG and/or IGT are 
defined as pre-diabetic, and they have a higher risk of developing T2DM (ADA, 2014). 
Pre-diabetes is a condition whereby the blood glucose levels are higher than normal 
but not high enough to be classified as T2DM according to WHO and ADA, respectively 
(WHO, 2011; ADA, 2014). The use of a FPG value of 7.0 mmol/L or greater, 
recommended by both the WHO and ADA as a diagnostic criterion for diabetes has 
several limitations. The limitations include the need for a confirmatory test on two 
separate occasions, the need for an eight hour fast and a 12 - 15% day to day variation 
(Petersen et al., 2005). The criteria recommended by WHO and ADA differ mainly on 
the lower limit of the FPG’s normal levels (WHO: <6.1 mmol/L and ADA: <5.6 mmol/L) 
(WHO, 2006; ADA, 2010). In South Africa, the WHO criterion of 1998 is adopted and 
 WHO criteria ADA criteria 
T2DM 
FPG 
2h-PG: 
HbA1c: 
RPG 
 
≥ 7.0 mmol/L 
≥ 11.1 mmol/L 
≥ 6.5%* 
≥ 11.1 mmol/L¥ 
 
≥ 7.0 mmol/L 
≥ 11.1 mmol/L 
≥ 6.5% 
≥ 11.1 mmol/L¥ 
IFG/IGT 
FPG: 
2h-PG: 
HbA1c: 
 
6.1-6.9 mmol/L 
7.8-10.9 mmol/L 
Not specified 
 
5.6-6.9 mmol/L 
7.8-11.0 mmol/L 
5.7-6.4% 
Normal 
FPG: 
2h-PG: 
HbA1c: 
 
<6.1 mmol/L  
<7.8 mmol/L 
Not specified 
 
<5.6 mmol/L 
<7.8 mmol/L 
<5.7% 
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the recommendations by the Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) also endorse the WHO criteria (WHO, 1999; Amod et al., 
2012). However, the SEMDSA recommendations do not replace professional 
judgment, experience and appropriate referral where applicable (Amod et al., 2012). 
 2h-PG = 2 hours-plasma glucose: a test which assesses glucose metabolism and 
clearance from the bloodstream, conducted by ingesting 75 g of glucose after an 
overnight fast of about eight hours and taking serial blood samples immediately before 
and two hours after the glucose drink.  
 RPG = random plasma glucose: when blood glucose levels are tested without a period 
of fasting. A value of more than 11.1 mmol/L, together with the classic symptoms of 
diabetes (polyuria, polyphagia, polydipsia, unexplained weight loss and fatigue) is 
considered to indicate diabetes, a diagnostic criteria common for both the WHO and 
ADA (WHO, 2006; ADA, 2010). A RPG value less than 11.1 mmol/L does not exclude 
diabetes and has to be followed up with another RPG or other diagnostic tests such as 
fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) and HbA1c. The 
RPG obviates the requirement for fasting, thus is particularly useful for rapid diagnosis.  
 The oral glucose tolerance test (OGTT) is also known as the glucose tolerance test 
(GTT) or the 2 hour plasma glucose (2h-PG) test. An OGTT is conducted by ingesting 
75g of glucose after an overnight fast of about eight hours and taking serial blood 
samples immediately before and two hours after the glucose drink. The OGTT 
assesses glucose metabolism and clearance of glucose from the blood stream (Seino 
et al., 2010). Limitations of the OGTT include poor reproducibility and the requirement 
for fasting (Ko et al., 1998; Patel & Macerollo, 2010). However, besides the limitations, 
the OGTT is considered as the gold standard of diabetes diagnosis (Ko et al., 1998). 
 The HbA1c test measures the percentage of glycated hemoglobin. This test assesses 
glycemic control over a period of about three months, the lifespan of red blood cells  
(Franco, 2012). During the lifespan of a red blood cell, glucose molecules bind to 
hemoglobin molecules through a process called glycosylation. The process, though 
gradual, is believed to be directly proportional to the amount of glucose in the 
bloodstream (Markris & Spanou, 2011). Therefore the test reflects average glucose 
control over a period of about three months. The HbA1c test has several advantages 
over FPG and OGTT, such as obviating the need for fasting; no fluctuations due to 
recent meals (HbA1c is a three month estimate) thus free of the 12 -15% day to day 
variance and decreased susceptibility to measurement variation due to conditions such 
as stress and illness) (Saudek et al., 2008; ADA, 2014). However, limitations of HbA1c 
testing include greater cost, incomplete correlation between HbA1c and glucose 
concentrations in some individuals, limited availability and standardization in certain 
regions of the developing world, possible disparities due to race/ethnicity and 
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interference by anemia, as well as some medications (Saudek et al., 2008; Kumar et 
al., Ziemer et al., 2010; ADA, 2014). Furthermore conditions which shorten red blood 
cell survival, such as recovery from acute blood loss, pregnancy, blood transfusion and 
hemolytic anemia will falsely decrease HbA1c results (Markris & Spanou, 2011; ADA, 
2014). Therefore apparent that, like other current methods of diagnosis, HbA1c testing 
has limitations.  
 Taken together, it is apparent that the current methods of diabetes diagnosis are not 
without limitations, creating the need for the identification of other methods of 
diagnosis. Epigenetic changes especially in miRNA expression offers an option as a 
good marker for diabetes, and also as a promising diagnostic and prognostic marker 
of glucose intolerance (Bartel, 2004; Engels and Hutvagner, 2006 and Pillai et al., 
2007).  
1.3. Epigenetics 
 
1.3.2. Definition of epigenetics 
 
This word was first defined as “interaction between genes and their environment” emphasizing 
that epigenetic mechanisms are different in response to a given environment (Bird, 2002). 
Even though there is no uniform definition for epigenetics, it has been widely described as 
heritable changes in gene function and/or expression which do not change the nucleotide 
sequence (Bird, 2007; Christensen and Marsit, 2011). miRNAs are short noncoding RNAs that 
have elicited immense interest in recent years (Kato et al., 2013). They have been found to be 
associated in the molecular mechanisms of epigenetics, which also involve DNA methylation, 
lysine methylation in histones, histone acetylation, histone phosphorylation and RNA 
interference such as RNA induced silencing complex (RISC) and small interfering RNA 
(siRNA) (Kato et al., 2013). miRNA is also involved in chromosomal silencing and gene 
activation via binding protein complexes (Tchurikov, 2005).  
Changes in the expression of miRNAs have also been associated with a number of human 
diseases, indicating that miRNA expression levels are closely associated with the 
developmental, physiological, as well as disease processes (Betel et al., 2008; Li et al., 2009; 
Almen et al., 2012; Chen et al., 2012). They function mainly by regulating post-transcriptional 
gene expression by binding to their target messenger RNAs (mRNAs), leading to mRNA 
degradation and suppression of translation or even gene activation (Chen et al., 2012). In 
recent years, a technique using real-time quantitative reverse transcription-PCR (RT-PCR) 
was developed to investigate miRNA in serum/plasma (Dasi et al., 2001; Tsui et al., 2002 and 
Izzotti et al., 2018), which can facilitate research in this area, including the possible 
identification of individuals with an increased risk of developing T2DM. This could prevent the 
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clinical onset of the multiple malfunctions and complications of T2DM. However, there is 
scarcity of studies on the involvement of circulating miRNAs in the serum of people with 
glucose intolerance (Izzotti et al., 2018). 
1.3.3. MicroRNAs (miRNA) 
 
miRNAs are a class of small, endogenous, noncoding RNAs approximately 19-22 nucleotides 
in length that modulate gene expression (Poy et al., 2004). MicroRNA was first identified in 
1993, by Ambros and his group. These molecules are found in plants, animals and some 
viruses and were only identified in humans in the last decade (Rooij, 2011). Generally, miRNAs 
exert inhibitory effects on gene expression by binding to the 3′- untranslated (UTR) of their 
mRNA targets hence causing gene silencing by mRNA cleavage or degradation as seen in 
Figure 1.1, thus modulating physiological and pathological processes (Rooij, 2011). Currently 
the biological functions of miRNAs are actively being sought. Some studies have notably 
uncovered roles for miRNAs in cellular processes including apoptosis, proliferation, stress 
resistance, tumorigenesis, defense against pathogenic infections, neural development and 
metabolism (Izzotti et al., 2018 and Matsha et al., 2018).  
1.3.4. Biogenesis of microRNAs 
 
Figure 1.1, shows the biogenesis of miRNA which begins in the nucleus. The primary miRNAs 
are transcribed by RNA polymerase II (Bartel, 2004) and cleaved by Drosha, a nuclear RNAse 
III enzyme (Han et al., 2004). The resulting pre-miRNA is transported into the cytoplasm and 
processed into double-stranded miRNA by Dicer, an RNAse III enzyme. One strand of this 
duplex represents the mature miRNA and is assembled into the RNA-induced silencing 
complex (RISC), while the other strand of this duplex is degraded. MicroRNA incorporated into 
the RISC regulates expression of genes by translational repression or degradation of mRNA, 
which depends on complementarity of sequence between mRNA 3′ UTR region and miRNA 5′ 
region (Bartel, 2004; Engels and Hutvagner, 2006; and Pillai et al., 2007). This target 
recognition occurs through the miR “seed” sequence, which is comprised of the first 8 
nucleotides of the mature miRNA molecule (Bartel, 2009).  
Targets for miRNAs may be approximately 60% of mRNAs. miRNAs have a role in controlling 
the signaling pathways in many types of cells and in phenotype and development of cells of 
the immune system as well as regulation of the inflammatory response in many tissues (Perry 
et al., 2015). In addition, miRNAs are emerging as markers of disease diagnosis and 
prognosis, and as new therapeutic targets. Following the discovery of extracellular miRNA in 
blood plasma and serum, miRNAs are also found in all other body fluids including; saliva, urine, 
breast milk, seminal fluid, tears, amniotic fluid, colostrum, bronchial lavage, cerebrospinal fluid, 
peritoneal fluid, and pleural fluid (Gregory et al., 2006). Both total miRNA concentration and its 
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relative composition vary significantly among different fluid types (Perry et al., 2015). 
Furthermore, the changes in miRNA spectra observed in certain fluids correlate with various 
pathological conditions, suggesting that extracellular miRNAs can serve as informative 
biomarkers to assess the pathological status of the body (Gregory et al., 2006). 
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Figure 1.1: Biogenesis of micro RNA (Adapted from: Moore et al., 2011)
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Foot notes 
Figure 1.1, shows the miRNA biogenesis pathway. MicroRNAs are transcribed in the nucleus 
by RNA polymerase from independent miRNA genes located in polycistronic transcripts or 
introns of protein-coding genes into primary transcripts (pri-miRNAs) (Kathryn et al., 2011). 
Pri-miRNAs are processed in two steps in the nucleus and cytoplasm by the RNase III–type 
endonucleases Drosha and Dicer, respectively, in complexes with dsRNA-binding domain 
proteins DGCR8 and TRBP, as indicated (Kathryn et al., 2011). In the canonical pathway, 
Drosha-DGCR8 processes the transcript to a stem-loop-structured precursor (premiRNA) 
(Kathryn et al., 2011). Alternatively, miRtrons, a subset of miRNAs derived from introns, may 
be processed into premiRNAs by the spliceosome and the debranching enzyme (Kathryn et 
al., 2011). Both canonical miRNAs and miRtrons are exported to the cytoplasm via Exportin 5, 
where they are further processed by Dicer to yield ≈20-bp miRNA duplexes (Kathryn et al., 
2011). One strand is selected to function as the mature miRNA and loaded into the RNA-
induced silencing complex (RISC) containing components of the Argonaute family (Ago 1–4), 
while the partner miRNA∗ strand is preferentially degraded (Kathryn et al., 2011). A subset of 
miRNAs, exemplified by miR-451, is produced independently of Dicer through recognition by 
Ago2 (Kathryn et al., 2011). The mature miRNA produced by these two mechanisms leads to 
translational repression or degradation of the target mRNA (Kathryn et al., 2011). Animal 
miRNAs usually show only partial complementarity to the target mRNA promoting translational 
repression or deadenylation coupled to exonucleolytic degradation of target mRNA (Kathryn 
et al., 2011). 
 
1.4. Role of microRNAs in diabetes 
 
The role of miRNAs in the function of β-cells in T2DM patients has been extensively studied 
but is not yet fully understood (Poy et al., 2004). A role for miRNAs in T2DM was first 
established in 2004 showing that miR-375 is directly involved in the regulation of insulin 
secretion (Poy et al., 2004). This study was one of the first to demonstrate that a miRNA could 
be tightly linked to a disease phenotype. In recent years, many additional miRNAs have been 
identified as components of pathways triggered by, or contributing to, the pathology of both 
T1DM and T2DM (ADA, 2011). Due to the multifactorial and polysystemic nature of this 
disease and the increased interest in miRNAs, many more miRNAs will be identified as 
important markers in diabetes (ADA, 2011). Recently, many other miRNAs have been found 
to be associated with diabetes and the complications that result from hyperglycemia (Matsha 
et al., 2018). In this study, a good number of miRNAs were investigated. This will undoubtedly 
lead to a greater understanding of the disease and provide novel diagnostic, prognostic 
alternative. 
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1.5. Motivation for this study 
 
1.5.1. Problem Statement 
Type 2 diabetes mellitus, a complex, multifactorial metabolic disorder that is caused by genetic 
and environmental factors, is a major source of morbidity and mortality worldwide. Intensive 
research is aimed at improved diagnosis and management of the disease. The mixed ancestry 
population of South Africa, commonly referred to as ‘coloureds’ has a high prevalence of 
diabetes (Erasmus et al., 2012). Furthermore, this population has also been reported to have 
high rates of obesity and metabolic syndrome, and therefore at a high risk of developing CVD 
(Matsha et al., 2012). Follow-up studies have shown that the accelerated deterioration of 
glucose tolerance status over time is not only explained by the known determinants of diabetes 
occurrence, rather by other yet to be identified factors which include those involved in 
epigenetic mechanisms such as miRNAs (Matsha et al., 2013).  
1.5.2. Rationale 
 The identification of individuals who are at risk of developing T2DM could facilitate 
intervention to delay or prevent the progress of the disease, thus minimizing the burden 
of T2DM. Interventions to protect against insulin resistance and β-cell dysfunction by 
lifestyle modifications or therapeutic drugs may reverse the disease phenotype and 
prevent the progression to T2DM. Identifying individuals with an increased risk of 
developing T2DM, before the clinical onset of these multiple malfunctions and 
complications is a major priority in glucose intolerance. To date there are no biomarkers 
that can facilitate identification of individuals who are at risk of developing T2DM. 
Biomarkers available are used for testing and monitoring T2DM, and these include 
blood glucose and glycated haemoglobin. Investigating the role of miRNAs in the 
development of T2DM may contribute to the better understanding of the mechanisms 
involved in the initial stages of T2DM, and hopefully identification of at risk individuals 
prior to occurrence of associated complication. To date there are no biomarkers that 
can facilitate identification of individuals who are at risk of developing T2DM. 
Biomarkers available are used for testing and monitoring T2DM, and these include 
blood glucose and glycated hemoglobin. Investigating the role of miRNAs in the 
development of T2DM may contribute to the better understanding of the mechanisms 
involved in the initial stages of T2DM, and hopefully identification of at risk individuals 
prior to occurrence of associated complication.   
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1.5.3.  Hypothesis 
Glucose intolerance is associated with altered expression of circulating miRNA which may be 
an early detection marker 
1.5.4.  Aim 
To investigate the expression profile of circulating miRNAs as a prognostic marker in subjects 
with glucose intolerance 
 
1.5.5. Objective 
 
• To identify miRNAs that are differentially expressed in individuals with glucose 
intolerance 
• To determine whether miRNAs expression is affected by diabetes associated 
conditions such as obesity  
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2: RESEARCH DESIGN AND METHODOLOGY 
 
2.1. Ethics 
Ethical clearance for conducting the study in human subjects was sought and obtained from 
the Cape Peninsula University of Technology Health and Wellness Sciences Research Ethics 
Committee (HW-REC)+,Registration Number NHREC: REC- 230408-014  
2.2. Study design 
A quantitative cross sectional study design involving 36 individuals [who were age, gender and 
BMI (Body Mass Index) matched] from a total population of 1989 participants of mixed ancestry 
descent, residing in Bellville South, South Africa was used. Quantitative methods were used 
to investigate the epigenetic changes corresponding with the expression of circulating miRNA 
in the serum of participants from the Belhar and Bellville South community, Cape Town, South 
Africa. miRNA present in serum was the dependent variable and was compared to the 
independent variable, disease status (diabetic, pre-diabetic and controls). The association of 
other variable factors such as gender and age was also compared to the results obtained 
above.  
2.3. Study population  
The enrolment of participants for this study was conducted from 2014 to 2016. A total of 1989 
subjects were enrolled. Participants for this study were selected from participants recruited 
from Bellville South and Belhar, Cape Town, South Africa.The inclusion criteria were: all 
coloured participants who enrolled in the study on a voluntary basis and gave informed 
consent. The exclusion criteria were; subjects less than 16 or older than 95 years of age, 
pregnant women, those who did not volunteer to participate in the study, and acutely ill 
participants.  
All participants signed informed written consent and were informed about their rights, and their 
involvement in the research. Furthermore, all study procedures were explained to participants 
in their language of choice. Participants were also informed of their right to freely withdraw 
from the study whenever they wanted to. Information about the participants and aspects of the 
study were kept confidential. The study was conducted according to the Code of Ethics of the 
World Medical Association (Declaration of Helsinki). The total number of participants used 
were, 36 females, making a group of three (with 12 participants each), according to the three 
status’ under investigation in this study [Diabetic (DM), pre-diabetic (preDM) and (control) 
individuals] and they were age, gender and BMI matched. 
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2.4. Experimental outline 
 
Stored serum samples collected from participants from Belhar or Bellville South were used in 
this study for investigating the expression of circulating miRNA in mixed ancestry subjects who 
were diabetic, pre-diabetic and control. This involved the purification of circulating miRNA from 
serum, followed by identification of the various miRNAs which could possibly serve as 
biomarkers for glucose intolerance. 
2.5. Data collection 
Clinical and biochemical data were collected by the research team which comprised of 
professional nurses and field workers. Field workers were pre-trained individuals involved in 
the recruitment of participants and for the collection of clinical and biochemical data. The 
clinical and biochemical data were collected as follows; 
2.6. Clinical data 
2.6.1. Questionnaire 
The questionnaire requested information about the participant’s demographics such as 
gender, age, previous medical history of diabetes, dietary, as well as lifestyle aspects. The 
four components of the questionnaire were: i) personal demographics, ii) family health history, 
iii) diet and iv) cigarette smoking. The questionnaire was adopted from other standard and 
recognized sources such as the CAGE Questionnaire (Ewing, 1984), the South African 
Demographic and Health Survey Report by the South African Medical Research Council 
(SADHSR) (Bradshaw et al., 1995; Goedecke et al., 2005). The SADHSR questionnaire 
focuses on chronic and lifestyle diseases by addressing the diabetic status, nutritional status, 
hypertension and physical activity of the participants. The CAGE questionnaire is mainly used 
in alcohol related studies. The questionnaire used for this study was also adopted from a 
previous study to measure the prevalence of DM amongst learners attending schools in the 
Belhar, Delft and Mfuleni suburbs in the Cape Town metropole (Somers et al., 2006). The 
family health history section of the questionnaire covered the presence or previous treatment 
of family members, up to third degree relatives, for related inheritable diseases. The section of 
the questionnaire on cigarette smoking focused on: a) the particular habit, b) duration of the 
habit, c) quantity or amounts consumed, and d) when the habit was stopped. A detailed 
medication history was obtained by asking participants, as well as examining their clinic cards, 
and recording the drugs which they brought to the study site. 
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2.6.2. Clinical measurements 
Clinical measurements obtained included: height, weight, waist and hip circumference, blood 
pressure measurements and blood collection. All anthropometric measurements were done 
three times and the average of these measurements used for the final analysis. 
2.6.2.1.  Height 
A portable stadiometer was used to measure height with the readings recorded in centimeters 
(cm). A participant was asked to stand on the flat surface of the stadiometer, without their 
shoes, at right angles to the vertical sliding lever of the stadiometer. The head was then placed 
in the Frankfort plane with hands freely at the sides. The scapular and buttocks were placed 
as close to the vertical sliding metallic bar as possible to ensure accurate readings. The sliding 
metallic bar was then allowed to gently rest on the subject’s head. If the participant was taller 
than the investigator, the investigator stood on a platform to enable an accurate reading.  
2.6.2.2. Weight 
A calibrated and standardized Sunbeam EB710 digital bathroom scale was used to measure 
participants’ weight in kilograms (kg). Participants were weighed in light clothing and were also 
asked to remove shoes and socks. The weight of all participants, except wheelchair bound or 
those who were posturally impaired were measured. The participant would stand on the middle 
of the flat surface of the scale after it had been zeroed. Hands were placed on the sides and 
after ensuring that the subject’s weight was evenly distributed, the reading was taken. 
Readings less than 0.5 kg were rounded off to the nearest lower kilogram while those above 
0.5 kg were rounded off to the nearest higher kilogram. The body mass index (BMI) was 
calculated by dividing the weight and height squared [weight/height2] (kg/m2). 
2.6.2.3.  Waist circumference 
A non-elastic tape that had been inspected for calibrations and stretch was used to measure 
the waist circumference (WC). Subjects were asked to stand in an erect position with hands 
placed on their sides and with their feet and abdominal muscles relaxed. Measurements were 
taken with the investigator in front of the participant, and by placing the measuring tape around 
the natural waist (narrowest part of the torso as seen from the anterior view). For obese 
participants, the narrowest circumference between the ribs and the iliac crest was measured 
(Tolonen et al., 2002). 
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2.6.2.4. Hip circumference 
The hip circumference (HC) was measured at the maximal circumference over the buttocks. A 
non-elastic tape was also used for this measurement. The investigator would squat before the 
subject with the tape placed around the buttocks on the widest area over the horizontal plane 
without pressing tightly against the skin, and the measurement taken. When the hip 
circumference exceeded the tape size, the measurement was not recorded, but noted 
(Tolonen et al., 2002) 
2.6.2.5. Blood pressure measurements 
Measurements used to assess the blood pressure were systolic blood pressure and diastolic 
blood pressure. Systolic blood pressure (SBP) refers to the highest arterial pressure as a result 
of the exertion of the blood upon the walls of the blood vessels (arteries) immediately after the 
pumping action of the left ventricle of the heart. Diastolic blood pressure, in contrast, refers to 
the lowest arterial blood pressure when the heart muscles contract after a systolic event 
(Pickering et al., 2005). Blood pressure is expressed as SBP over DBP, with the ratio (as a 
fraction) taken as the blood pressure and the units are millimeters of mercury (mm Hg) 
(Pickering et al., 2005). Blood pressure measurements were done according to WHO 
guidelines (WHO, 1999). Blood pressure measurements were taken using a calibrated 
baumanometer (Rossamax; Berneck, Switzerland) with the participant in a relaxed sitting 
position. Participants were allowed to sit with their back supported on the chair backrest, while 
their arms were exposed and rested on the table at the same level as their heart. The correct 
adult cuff size was placed 2cm above the elbow joint to ensure accurate readings (Pickering 
et al., 2005). Three readings, at one minute intervals, were taken and the lowest reading was 
chosen as the participant’s blood pressure. During the time of taking the measurement, the 
participants were not allowed to speak as this has been found to affect the readings (Adams 
et al., 2002; Panchón et al., 2004). 
2.6.2.6.  Blood collection 
 
Six blood tubes were collected for each participant: three fasting and three postprandial bloods. 
Self-reported T2DM participants (confirmed by either medical records or medications) had only 
the fasting blood samples taken and no 2 hour bloods were drawn. Both the fasting and 
postprandial blood samples were collected in one grey capped-tube (sodium fluoride), one 
plain tube (no clotting factors) and one purple capped-tube Ethylene diamine tetra-acetic acid 
(EDTA). The grey top tubes were used to measure blood glucose concentrations, while the 
plain top tubes were used to obtain serum for miRNA extraction and serological tests such as 
serum cotinine, insulin and lipid profile. The purple capped-tubes were used to measure 
HbA1c. 
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2.6.2.7. The oral glucose tolerance test (OGTT) 
All participants, excluding the self-reported diabetic subjects (confirmed by either participant 
medical card record or drug use), underwent the oral glucose tolerance test (OGTT). Subjects 
were asked to fast overnight where after the OGTT was conducted according to WHO 
guidelines (WHO, 1999) as follows: i) investigators asked participants whether they had fasted, 
ii) collected fasting blood samples, iii) gave participants 75 grams of anhydrous glucose 
dissolved in 250 - 300ml of water, which was drunk within 3 - 5 min, and the time recorded, iv) 
collected a second blood sample after 2 hours (2h-PG). Phlebotomy was conducted by trained 
nurses. 
2.7. Biochemical data 
Biochemical measurements including fasting plasma glucose (FPG) and 2h-PG plasma 
concerntrations, glycosylated haemoglobin (HbA1c), serum insulin, triglycerides, cholesterol, 
gamma glutamyl-transferase (GGT) enzyme and cotinine were conducted as described 
previously (Matsha et al., 2012). Plasma glucose concentrations were measured using the 
hexokinase method (Cobas 6000, Roche Diagnostics; Mannheim, Germany). The HbA1c was 
measured using the turbidimetric inhibition immunoassay (Cobas 6000, Roche Diagnostics). 
This method is certified by the National Glycohemoglobin Standardization Programme (NGSP) 
according to Roche Diagnostics. High density lipoproteins (HDL), gamma glutamyl-transferase 
(GGT) and triglycerides were estimated using enzymatic colorimetric methods (Cobas 6000, 
Roche Diagnostics). Low density lipoproteins (LDL) were calculated using the Friedwald’s 
formula (Friedewald et al., 1972). C-reactive protein (CRP) concentration was measured with 
a Beckman nephelometer auto-analyzer (Beckman, South Africa). Insulin was measured using 
a microparticle enzyme immunoassay (Axsym, Abbot, Princeton, USA). Serum cotinine was 
measured using a chemiluminescent assay (Immulite 1000, Siemens). 
2.8. Quality control procedures 
The study was conducted adhering to strict standard operating procedures (SOPs).  Field 
workers and nurses involved in the study were briefed on how to take blood pressure, blood 
collection, anthropometric measurements and questionnaire administration. Researchers were 
required to sign off on questionnaires, blood pressure and collection, as well as anthropometric 
measurements that they conducted in order to trace and verify measurements and data 
entries. Spot field checks were also conducted by project supervisors in order to verify the 
accuracy of measurements and enhance quality control (Adams et al., 2002). Equipments 
were routinely calibrated according to the manufacturer’s instructions. Scales were routinely 
checked for accuracy using standard weights. The work-load of all staff involved in the study 
was kept within acceptable limits in order to avoid false measurements due to staff fatigue. 
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Each team had a supervisor who was responsible for monitoring performance and who was 
also responsible for equipment calibration. Weekly meetings were held to assess progress, 
problem-solving, and retraining if necessary. 
2.9. Sample for the study 
Blood samples for this study were collected from mixed ancestry participants from Ward 009, 
Cape Town, South Africa, from 2014 to 2016. For the extraction of circulating miRNAs, whole 
blood samples were collected from participants in BD Vacutainer (SST), subjected to 
centrifugation at 1900 × g (3000rpm) for 10 minutes at room temperature.  Serum aliquots 
were stored in RNAse free freezing vials at -80ºC, to be used for the extraction of circulating 
miRNAs in this study. After which a quantitative analysis of the circulating miRNA present in 
the various samples were ascertained using Real Time Polymerase Chain Reaction as follows. 
2.10. MicroRNA extraction/purification  
 
Frozen serum samples which were stored at -800C were thawed and used for miRNA 
extraction. The QiagenmiRNeasy Serum/Plasma Kit (Whitehead Scientific, Cape Town) was 
used for the extraction: 
1000 μl of QIAzolLysis Reagent Mix was added to 200μl serum samples. Samples were 
vortexed and incubated at room temperature (15–25°C) for 5min. 3.5μl miRNeasy 
Serum Spike-In Control (1.6 x 108copies/μl working solution) was added and mixed 
thoroughly. Then 200μl Chloroform was added to the tube containing the lysate and 
capped securely. The samples were then vortexed for 15s and incubated at room 
temperature (15–25°C) for 2–3min. Furthermore, samples were centrifuged for 15min 
at 12,000 x g at 4°C. After centrifugation, the centrifuge was heated up to room 
temperature (15–25°C). The upper aqueous phase was then transferred to a new 
collection tube. 300μl of 100% ethanol was added and mixed thoroughly by pipetting 
up and down several times. Immediately 700μl of the samples was pipetted, including 
any precipitate that may have formed, into an RNeasyMinElute spin column in a 2 ml 
collection tube. 
The lid was gently closed and centrifuged at 8000xg (10,000 rpm) for 15s at room 
temperature (15–25°C) and the flow-through was discarded. This step was repeated 
with the remaining sample.700μl Buffer RWT was added to the RNeasyMinElute spin 
column and centrifuged for 15s at 8000xg (10,000 rpm) to wash the column and the 
flow-through discarded. Then 500μl buffer RPE was pipetted onto the RNeasyMinElute 
spin column and centrifuged for 15s at 8000xg (10,000 rpm) to wash the column and 
the flow-through was discarded. 500μl of 80% ethanol was pipette onto the 
RNeasyMinElute spin column and centrifuged for 2min at 8000xg (10,000rpm) to wash 
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the spin column membrane. The collection tube with the flow through were discarded. 
The RNeasyMinElute spin column was then placed into a new 2ml collection tube, the 
spin column was left open while centrifuging at full speed for 5min to dry the membrane. 
The collection tube and flow-through were then discarded and RNeasyMinElute spin 
column was placed in a new 1.5ml collection tube and 14μl RNase-free water was 
added directly to the center of the spin column membrane and centrifuged for 1min at 
full speed to elute the miRNA. Elute contained extracted miRNA as seen in Figure 2.1 
below. Extracted miRNA was then reverse-transcribed to obtain cDNA for RT-PCR. 
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Fig 2.1: Micro RNA Extraction/Purification (Adapted from Qiagen miRNeasy 
Serum/Plasma 2014 Manual, ThermoFisher Scientific, Massachusetts, USA) 
 
  23 
 
2.11. Reverse transcription (cDNA synthesis) 
The cDNA synthesis was done using the Qiagen RT2 First Strand Kit (ThermoFisher Scientific). 
The reagents of the RT2 First Strand Kit were thawed and briefly centrifuged (10–15s) to bring 
the contents to the bottom of the tubes. The genomic DNA elimination mix was prepared for 
each RNA sample and mixed gently by pipetting up and down and then briefly centrifuged 
(samples were amplified in singletons). It was incubated for 5min at 42°C, then immediately 
placed on ice for at least 1min. The reverse-transcription mix was prepared and 10μl of it was 
added to each tube containing 10μl genomic DNA elimination mix and mixed gently by pipetting 
up and down. Mixture was incubated at 42°C for 15min and reaction was stopped by 
immediately incubating at 95°C for 5min using BIO RAD (T100THThermal Cycler). cDNA 
concentrations and purity were then analyzed using nano-drop machine and the average purity 
of samples were 1.8 for the 260/280 OD and 2.0 for the 260/230 OD. Dilutions of cDNA yielded 
were made at (3ng of cDNA in 300µl of nuclease free water). Diluted samples were then stored 
at the -20°C prior to real-time PCR. 
2.12. Real time polymerase chain reaction  
 
The Qiagen miScript SYBR Green PCR kit (ThermoFisher Scientific) was used with miScript 
miRNA PCR Arrays for the real time polymerase chain reaction. Prior to preparing real-time 
PCR reaction mixes all reagents (2x QuantiTectRSYBR Green PCR Master Mix, 10x miScript 
Universal Primer and RNase-free water) (ThermoFisher Scientific) were allowed to thaw. The 
master mix was prepared as seen on table 2.1. 
Table 2.1: Contents of PCR Master Mix 
Array Components 96 wells 
2x QuantiTect SYBR Green PCR   
Master Mix 
1375 µl 
10x miScript Universal Primer 275 µl 
RNase-free water 1000 µl 
Template cDNA 100 µl 
Total volume 2750 µl 
 
The array was removed from its sealed bag, and 25μl reaction mix added per well and tightly 
sealed with caps which were then centrifuged for 1min at 1000x to bring content to the bottom 
and to take out all the bubbles. Array plates were placed into the QUANT STUDIO 7 machine 
for the RT-PCR. Initial activation and pre-heating step was done at 95ºC for 15 min to activate 
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the HotStarTaq DNA Polymerase, followed by the Real Time PCR with cycle conditions as 
seen below. 
3-step cycling; Denaturation 15s at 94ºC 
            Annealing 30s at 55 ºC 
            Extension 30 s at 70ºC, 40 cycles were done for all miRNAs 
 
2.13. Differential expression miRNAs 
Differential expression of the miRNAs was done by quantifying amplified cDNA as follows; 
At the end of the 40 cycles of the RT-PCR, the cycle threshold values (CT values) of each 
miRNA were read from 1 and above. All CT values greater than 35 or N/A (not detected 
/undetermined) were reported as 35. At this point, any CT value equal to 35 was considered a 
negative call. 
 
The ΔCT for each pathway-focused gene in each plate was calculated using the CT values for 
the gene of interest (GOI) and the housekeeping genes (HKG) used for normalization using 
the formula:  ΔCT = CTGOI – CTAVG HKG. 
When biological experiments were performed, the average ΔCT value of each gene (each well) 
was calculated across the replicate arrays for each treatment group. 
 
The ΔΔCT for each gene across 2 RT2 Profiler PCR Arrays (or groups of samples) was 
calculated using the formula: ΔΔCT = ΔCT (group 2) – ΔCT (group 1), where group 1 was 
group of control samples and group 2 was group of experimental samples. 
The fold-change for each gene from group 1 to group 2 was calculated as:  2 (-ΔΔCT).  
The results were reported as; if the fold-change was greater than 1, the result was reported as 
a fold up-regulation. If the fold-change was less than 1, the negative inverse of the result was 
reported as a fold down-regulation. Fold-change ratio calculations were unreliable when raw 
CT values from both groups were greater than 35. 
2.14. Statistical analysis 
 
Statistical analysis of circulating miRNA data was performed using STATISTICA 13 (StatSoft 
Inc., Tulsa, USA). The selected samples were age, gender and BMI matched. The mean ± SD 
(used for clinical parameters apart from glucose tests) and where applicable the median ± 
range (used for glucose tests) were used to establish differences between groups, with a p-
value of <0.05 considered to be statistically significant, using ANOVA and the Kruskal-Wallis 
test respectively. Correlations were done using the Spearman Rank Order Correlations (r). 
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CHAPTER 3: RESULTS 
 
3.1. The clinical characteristics of participants  
 
 The clinical characteristics of the study participants and other biochemical parameters 
according to glucose tolerance status are summarized in Table 3.1: The participants for this 
study were chosen from the 2014-2016 study with a total of 1989 participants. Participants 
were both male and female, with the female population more than the males. Only females 
were involved in this study and they were age and BMI matched. They were chosen 
chronologically from the first participants to the number needed for this study and according to 
their glycemic status’ [control, pre-diabetes (preDM) and diabetes (DM)]. Serum from 36 
female participants selected was used as the sample for the study. Participants were evenly 
distributed amongst the three groups, that is, 12 participants per group. 
 
There were significant differences between groups in the waist (cm) (p=0.0415) and waist/hip 
ratio (p=0.0011) with highest values in the DM group and lowest in the normal group. Clinical 
parameters varied significantly according to glycemic status. As expected, the FBG (mmol/L) 
(p<0.0001), 2 HRs Post Glucose (mmol/L) (p<0.0001), HbA1c (%) (p=0.0009), Fasting Insulin 
(mIU/L) (p=0.0039), were all highest in the DM and lowest in the control group. In contrast, the 
2 HRs Post Insulin (mIU/L) (p = 0.0027) was highest in the pre-DM group and lowest in the 
normal group, while the Glucose/Insulin ratio (p=0.0477) was highest in the normal group and 
lowest in the pre-DM group. Trigs (mmol/L) (p=0.0043) and Total Chol (mmol/L) (p=0.0429) 
were significantly increased throughout the three groups, with highest values in the DM group 
and lowest in the normal group. 
  26 
 
 
Table 3.1: Clinical characteristics of participants 
 Total, N36 Normal, N12 PreDM, N12 DM, N12  
 Mean±SD [Median (25Q; 75Q)]* P-value 
      
Age (years) 53.4±7.8 52.1±7.8 53.5±8.5 54.8±7.5 0.7171 
BMI 31.5±8.4 27.3±5.8 33.3±9.1 33.5±8.9 0.1410 
Waist  circumference (cm) 93.9±18.7 83.2±18.5 97.1±13.8 101.3±19.7 0.0415 
Hip circumference (cm) 107.1±17.7 102.0±18.4 109.9±18.6 109.4±16.6 0.4875 
WHR (waist/hip ratio) 0.87±0.08 0.81±0.07 0.89±0.06 0.92±0.07 0.0011 
SBP (mmHg) 138.4±27.5 135.3±30.8 137.0±18.5 142.9±32.9 0.7843 
DBP (mmHg) 87.0±18.0 78.0±16.1 88.9±11.7 94.2±22.1 0.0768 
Pulse (bpm) 72.1±13.5 64.8±12.2 71.3±5.8 80.1±16.4 0.0163 
FBG (mmol/L)* 5.40 (4.80; 6.35) 4.75 (4.25; 4.90) 5.30 (4.95; 5.75) 7.90 (6.25; 11.15) <0.0001 
2 HRs Post Glucose (mmol/L)* 9.00 (7.20; 13.30) 5.20 (4.00; 7.20) 9.00 (8.55; 10.00) 15.10 (12.90; 19.50) <0.0001 
HbA1c (%)* 6.00 (5.45; 6.65) 5.55 (5.20; 5.75) 6.00 (5.35; 6.50) 7.05 (6.45; 9.15) 0.0009 
Fasting Insulin (mIU/L)* 8.10 (5.70; 12.50) 5.65 (2.95; 7.85) 9.45 (7.55; 12.50) 14.10 (5.90; 21.20) 0.0039 
2 HRs Post Insulin (mIU/L)* 53.20 (29.20; 97.90) 28.50 (17.80; 40.40) 111.20 (60.20; 187.20) 48.80 (31.45; 83.30) 0.0027 
Glucose/Insulin ratio* 0.70 (0.40; 0.90) 0.90 (0.65; 1.60) 0.60 (0.40; 0.70) 0.70 (0.40; 1.50) 0.0477 
Trigs (mmol/L)* 1.40 (0.94; 1.72) 0.94 (0.73; 1.26) 1.50 (1.11; 1.90) 1.72 (1.40; 2.84) 0.0043 
LDL-Chol (mmol/L) 3.64±0.98 3.30±0.96 3.46±0.96 4.18±0.84 0.0602 
HDL-Chol (mmol/L) 1.42±0.50 1.57±0.50 1.32±0.41 1.38±0.58 0.4514 
Total Chol (mmol/L) 5.75±1.05 5.51±1.10 5.39±0.98 6.36±0.85 0.0429 
Chol/HDL ratio 4.35±1.38 3.73±1.16 4.35±1.35 5.02±1.42 0.0786 
CRP (mg/L) 7.84±8.56 3.12±2.73 9.28±5.93 11.11±12.34 0.0520 
Cotinine (ng/mL) 129.8±144.1 131.8±150.9 130.2±144.7 127.4±149.5 0.9974 
Smokers (even no’s selected) 18/36 6/12 6/12 6/12 Not applicable 
Gamma GT-S (IU/L) 53.6±56.4 39.8±63.3 56.4±49.9 64.5±57.4 0.5623 
Drinkers, Yes %(N) 19.4% (7/36) 33.3% (4/12) 8.3% (1/12) 16.7% (2/12) 0.2890 
Parameters with (*) indicate median, while the means have no (*) attached  
Bold values indicate statistical significance (p < 0.05)
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3.2. Micro RNAs expressed in current study population  
 
In this study, a total of 84 miRNAs were used to evaluate the relationship between glucose 
intolerance and the circulating miRNAs in serum. A total of 54 miRNAs were expressed of 
which; 12 were expressed in all three groups (control, preDM and DM groups), 3 were 
expressed in two groups (control and DM groups) and 39 expressed in only one group (DM 
group) and are summarised in Table 3.2. 
Table 3.2: MicroRNAs expressed 
 
MicroRNAs 
expressed in all 
groups 
MicroRNAs expressed in normal and 
DM groups (not in PreDM) 
MicroRNAs expressed in DM 
group only 
let-7i-5p miR-324-5p miR-103a-3p, miR-125a-5p, miR-
129-2-3p, miR-130a-3p, 
miR-125b-5p miR-34c-5p miR-130b-3p, miR-135b-5p, miR-
152-3p, miR-184, 
miR-126b-5p miR-490-3p miR-194-5p, miR-195-5p, miR-
196-5p, miR-199a-5p, 
miR-129b-5p - miR-19a-3p, miR-206, miR-212-
3p,  
miR-143-3p - miR-214-3p, miR-24-3p, miR-27a-
3p,  
miR-146a-5p - miR-27b-3p, miR-296-5p, miR-
29b-3p, 
miR-200a-3p - miR-29c-3p, miR-30a-5p, miR-
30c-5p, 
miR-330-5p - miR-320b, miR-324-3p, miR-335-
5p,  
miR-382-5p - miR-34a-5p, miR-361-5p, miR-
370-3p, 
miR-451a - miR-375, miR-377-3p, miR-380-
5p, 
miR-542-3p - miR-381-3p, miR-424-5p, miR-
433-3p, 
miR-99b-5p - miR-4458, miR-4500, miR-7-5p, 
miR-96-5 
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3.3. Correlations 
 
3.3.1. Summary of correlations between expressed miRNAs and the clinical 
parameters are seen below  
  
These results were presented in 3 separate tables (tables 3.3, 3.4 and 3.5) for convenience 
because of the large number of variables: 
Correlation with anthropometric measurements (Table 3.3): Age (years) (r=-0.07928; 
p=0.0334) was significantly inversely correlated with miR-324-3p. The BMI was inversely 
correlated with miR-135-5p (r=-0.9000; p=0.0374) and miR-206 (r=-0.8286; p=0.0416). The 
waist (cm) was inversely correlated with miR-212-3p (r=-1.000; p<0.0001), miR-335-5p (r=-
0.8117; p=0.0499), miR-381-3p (r= -0.7928; p=0.0334) and miR-7-5p (r= -1.000; p<0.0001). 
The hip (cm) correlated inversely with miR-206 (r=-0.8117; p=0.0499) and miR-7-5p (r=-
0.9747; p=0.0048), while the WHR were negatively correlated with miR-324-3p (r=-0.9370; 
p=0.0019), miR-4458 (r=-0.8697; p=0.0244) and miR-96-5p (r=-0.8697; p=0.0244) but 
positively with miR-214-3p (r=0.7857; p=0.0362) and miR-308-5p (r=0.7857; p=0.0362). 
 
Correlations with FBG (mmol/L): The parameters used to determine the glycaemic status 
were correlated with the expressed miRNAs. There were significant inverse correlations 
between FBG and miR-130b-3p (r=-0.8469; p=0.0162), miR-146a-5p (r=-0.4595; p=0.0361), 
miR-200a-3p (r=-0.4622; p=0.0402), miR-330-5p (r=-0.4330; p=0.0271), miR-335-5p (r=-
0.8117; p=0.0499), miR-381-3p (r=-0.7748;p=0.0408), miR-4458 (r=-0.8117; p=0.0499) and 
miR-96-5p (r=-0.8117; p=0.0499). 
 
Correlations with 2 HRs Post Glucose (mmol/L): The 2 HRs Post Glucose showed inverse 
correlations with let-7i-5p (r=-0.4287; p=0.0366), miR-130b-3p (r=-0.9550; p=0.0008), miR-
146a-5p (r=-0.4902; p=0.0282), miR-200a-3p (r=-0.5667; p=0.0114), miR-330-5p (r=-0.4500; 
p=0.0240), miR-4458 (r=-0.8117; p=0.0499), miR-490-3p (r=-0.7909; p=0.0037) and miR-96-
5p (r=-0.8117; p=0.0499). 
 
Correlations with HbA1C (%): The HbA1C showed inverse correlations with miR-130b-3p 
(r=-0.9550; p= 0.0008), miR-29b-3p (r=-0.7748; p=0.0408), miR-330-5p (r=-0.4753; 
p=0.0141), miR-335-5p (r=-0.8117; p=0.0499), miR-382-5p (r=-0.4003; p=0.0156), miR-4458 
(r=-0.8117; p=0.0499), miR-490-3p (r=-0.6105; p=0.0461) and miR-96-5p (r=-0.8117; 
p=0.0499). 
 
Correlations with Fasting insulin (mIU/L): The Fasting insulin was inversely correlated with 
miR-135b-5p (r =-1.000; p<0.0001) and miR-424-5p (r=-0.8407; p=0.0361). 
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Correlations with 2 HRs Post insulin (mIU/L): The 2 Hrs Post insulin was inversely 
correlated with miR-184 (r=-0.8117; p=0.0499) and positively correlated with miR-125b-5p 
(r=0.4687; p=0.0209), miR-129-5p (r=0.5842; p=0.0086), miR-195-5p (r=0.8571; p=0.0137), 
miR-375 (r=0.7857; p= 0.0362), miR-377-3p (r=0.7545; p=0.0305), miR-4458 (r=0.9276; 
p=0.0077) and miR-96-5p (r=0.9276; p=0.0077).  
 
Summarily, the miRNAs involved in multiple glycaemic parameters were; miR-130b-3p, miR-
330-5p, miR-96-5p as well as miR-4458 were inversely correlated with FBG, 2HRs blood 
glucose Post Glucose and HbA1C, while, miR-330-5pmiR-96-5p correlated positively with 2 
HRs Post Insulin. MiR-146a-5pas well as miR-200a-3p was inversely correlated with FBG and 
2 HRs Post Glucose, while miR-335-5p was inversely correlated with FBG and HbA1c. MiR-
490-3p was inversely correlated with 2 HRs Post Glucose and HbA1c. 
 
Correlation of miRNAs with lipid profile (Table 3.5): Summarized significant correlations 
between the lipid test results and the expressed miRNAs. Trigs (mmol/L) (Table 3.4) was 
positively correlated with miR-129-2-3p (r=0.8117; p=0.0499) and inversely correlated with 
miR-29c-3p (r=-1.000; p<0.0001). 
HDL-Chol (mmol/L) (Table 3.5) was inversely correlated with miR-125b-5p (r=-0.4299; 
p=0.0284). There was no correlation between Total Chol (mmol/L) and any of the expressed 
miRNAs, while the Chol/HDL ratio was positively correlated with miR-30c-5p (r=0.9747; 
p=0.0048). 
 
Correlation of miRNAs with other pathophysiological markers (Table 3.5), the test for 
inflammation was positively correlated with miR-125b-5p (r=0.4632; p=0.0172) and inversely 
correlated with miR-206(r=-0.8286; p=0.0416), miR-212-3p (r=-0.9000; p=0.0374), miR-27b-
3p (r=-0.8286; p=0.0416), miR-335-5p (r=-0.8117; p=0.0499), miR-381-3p (r=-0.8469; 
p=0.0162) and miR-7-5p (r=-1.000; p<0.0001). GGT showed statistically inverse correlation 
with miR-99b-5p (r=-0.3908; p<0.0203) 
  
Summarily miRNAs involved with glycemic and inflammatory status were; miR-381-3p and 
miR-335-5p were also significantly inversely correlated with CRP, FBG and/or HbA1c
3.4. MicroRNAs fold changes in relation to clinical parameters 
 
Fold change is a measure describing how much a quantity changes, hence it compares 
between two levels of an entity being measured. In this study the fold change was used to 
describe the relationship between the miRNAs expressed and the glycemic states (control 
  
  32 
 
group/DM group, control/preDM and preDM/DM). A fold change equal to 1 implies no change, 
fold changes greater than 1 implies up-regulation and fold changes less than 1 
implies down-regulation. Table 4.1 shows a summary of fold changes of miRNAs that were 
expressed across all groups and those expressed just in two of the groups. The Ct values were 
the primary values obtained at the end of the RT-PCR cycles, and they indicated how much 
miRNA was able to produce fluorescence at a particular threshold. Lower Ct values implied 
more miRNAs were available to produce fluorescence at that threshold cycle reading.  
 
The Ct values were further used to calculate the fold changes of the miRNAs amongst the 
various groups being investigated in relation to the control group. Figure 4.1 demonstrates the 
fold changes of the 12 miRNAs expressed through all groups. As demonstrated in Figure 4.1 
shows let-7i-5p was up regulated in DM and preDM versus control. Let-7i-5p was found to be 
expressed more in preDM than in DM. Some miRNAs were expressed more in the controls 
than in preDM, but were expressed more in DM than in the former states. These miRNAs 
include; miR-125b-5p, miR-129b-5p, miR-146a-5p, miR-200a-3p, miR-451a and miR-542-3p. 
Interestingly, miR-126b-5p showed a consistent increase through all three groups; from the 
control to the preDM and then the DM group. MiR-143-3p, miR-330-5p and miR-382-5p were 
found to be expressed equally in both control and preDM but up-regulated in DM.  
Finally, miR-99b-5p was found to be equally expressed through all three groups. 
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Table 3.3: Correlations of Clinical Characteristics and expressed miRNAs 
 
  Age (years) BMI Waist (cm) Hip (cm) WHR SBP (mmHg) DBP (mmHg) 
MiRNA Number R P-value R P-value R P-value R P-value R P-value R P-value R P-value 
let-7i-5p 
 
25 -0.1090 0.6041 0.0096 0.9646 -0.176 0.3995 -0.0835 0.6915 -0.0615 0.7701 -0.4252 0.0341 -0.2773 0.1796 
miR-103a-3p 
 
7 -0.2883 0.5307 0.0180 0.9694 0.072 0.8780 0.0364 0.9383 0.3604 0.4271 -0.7091 0.0744 -0.1636 0.7259 
miR-125a-5p 
 
7 0.6071 0.1482 0.5357 0.2152 0.643 0.1194 0.2523 0.5852 0.7500 0.0522 0.0714 0.8790 0.0000 1.0000 
miR-125b-5p 
 
26 -0.0810 0.6939 0.2915 0.1574 0.064 0.7563 0.2282 0.2623 -0.0797 0.6989 -0.0304 0.8826 -0.0359 0.8616 
miR-126-5p 
 
20 0.0996 0.6761 0.2579 0.2864 0.141 0.5522 0.1843 0.4367 -0.0060 0.9799 -0.1662 0.4837 -0.0670 0.7791 
miR-129-2-3p 
 
6 0.3189 0.5379 0.2029 0.6998 -0.174 0.7417 -0.0588 0.9119 0.0290 0.9565 -0.1176 0.8243 -0.4118 0.4173 
miR-129-5p 
 
20 -0.2045 0.3872 0.4346 0.0555 0.158 0.5061 0.3213 0.1672 0.0541 0.8207 0.1828 0.4404 0.2853 0.2228 
miR-130a-3p 
 
8 0.0476 0.9108 0.2143 0.6103 0.095 0.8225 -0.2874 0.4900 0.5000 0.2070 -0.0476 0.9108 -0.1190 0.7789 
miR-130b-3p 
 
7 -0.1081 0.8175 0.1441 0.7578 -0.234 0.6132 -0.3424 0.4523 -0.2703 0.5577 0.2000 0.6672 0.0545 0.9075 
miR-135b-5p 
 
5 -0.2000 0.7471 -0.9000 0.0374 -0.600 0.2848 -0.8208 0.0886 0.4000 0.5046 -0.4000 0.5046 0.0000 1.0000 
miR-143-3p 
 
23 -0.1007 0.6474 0.0582 0.7971 -0.180 0.4116 -0.0722 0.7434 -0.0711 0.7470 -0.3495 0.1021 -0.0668 0.7620 
miR-146a-5p 
 
21 -0.0046 0.9843 0.1278 0.5912 -0.095 0.6827 0.0331 0.8866 0.1039 0.6540 -0.2209 0.3359 -0.1985 0.3884 
miR-152-3p 
 
9 -0.1255 0.7476 -0.1667 0.6682 0.283 0.4600 0.3096 0.4175 0.0833 0.8312 -0.2167 0.5755 -0.4435 0.2318 
miR-184 6 -0.0290 0.9565 -0.1449 0.7841 -0.203 0.6998 -0.1449 0.7841 0.3769 0.4615 0.1176 0.8243 0.4118 0.4173 
miR-194-5p 
 
7 -0.0357 0.9394 0.0000 1.0000 0.071 0.8790 -0.1441 0.7578 0.3929 0.3833 -0.3929 0.3833 -0.5357 0.2152 
miR-195-5p 
 
7 -0.1071 0.8192 0.4643 0.2939 0.321 0.4821 0.2162 0.6414 0.1429 0.7599 -0.2143 0.6445 -0.6429 0.1194 
miR-196-5p 
 
8 0.3333 0.4198 0.5238 0.1827 0.429 0.2894 0.0359 0.9327 0.5476 0.1600 0.0238 0.9554 -0.3571 0.3851 
miR-199a-5p 
 
7 0.3929 0.3833 -0.0714 0.8790 0.071 0.8790 -0.2523 0.5852 0.4643 0.2939 -0.3929 0.3833 -0.9643 0.0005 
miR-19a-3p 
 
7 0.2500 0.5887 0.1429 0.7599 0.393 0.3833 0.0721 0.8780 0.5357 0.2152 -0.6429 0.1194 -0.8214 0.0234 
miR-200a-3p 
 
20 0.0460 0.8472 0.1684 0.4907 -0.006 0.9799 0.0918 0.7003 0.0556 0.8158 0.0241 0.9198 0.0203 0.9322 
miR-206 
 
6 0.0286 0.9572 -0.8286 0.0416 -0.771 0.0724 -0.8117 0.0499 0.2571 0.6228 -0.2571 0.6228 -0.0286 0.9572 
miR-212-3p 
 
5 -0.7000 0.1881 -0.6000 0.2848 -1.000 0.0001 -0.8721 0.0539 -0.4000 0.5046 -0.3000 0.6238 0.0000 1.0000 
miR-214-3p 
 
7 0.5357 0.2152 0.2500 0.5887 0.393 0.3833 -0.2500 0.5887 0.7857 0.0362 0.1071 0.8192 -0.2857 0.5345 
miR-24-3p 
 
7 0.3571 0.4316 0.6786 0.0938 0.607 0.1482 0.4865 0.2682 0.3214 0.4821 0.1071 0.8192 -0.6786 0.0938 
miR-27a-3p 
 
5 -0.3000 0.6238 0.1000 0.8729 0.300 0.6238 0.1000 0.8729 0.0000 1.0000 -0.3000 0.6238 -0.8000 0.1041 
miR-27b-3p 
 
6 0.2571 0.6228 -0.3714 0.4685 -0.4286 0.3965 -0.6088 0.1997 0.3714 0.4685 -0.2000 0.7040 -0.8286 0.0416 
miR-296-5p 
 
8 0.3114 0.4528 -0.2395 0.5678 -0.1078 0.7995 -0.3735 0.3621 0.2275 0.5878 -0.2289 0.5855 -0.8795 0.0040 
miR-29b-3p 
 
7 0.5045 0.2482 0.1802 0.6990 0.0541 0.9084 -0.3063 0.5040 0.0901 0.8477 0.091 0.8463 -0.2364 0.6099 
miR-29c-3p 
 
5 0.4000 0.5046 0.4000 0.5046 0.4000 0.5046 -0.1000 0.8729 0.7000 0.1881 -0.400 0.5046 -0.3000 0.6238 
miR-30a-5p 
 
6 0.3189 0.5379 0.0290 0.9565 0.3189 0.5379 0.0290 0.9565 0.4928 0.3206 -0.941 0.0051 -0.8235 0.0440 
miR-30c-5p 
 
6 0.0290 0.9565 -0.0290 0.9565 0.2029 0.6998 -0.0290 0.9565 0.3189 0.5379 -1.000 0.0001 -0.7647 0.0765 
miR-320b 
 
6 0.0870 0.8699 -0.6667 0.1481 -0.4928 0.3206 -0.6667 0.1481 0.0290 0.9565 -0.412 0.4173 -0.7647 0.0765 
miR-324-3p 
 
7 -0.7928 0.0334 -0.2883 0.5307 -0.4324 0.3325 -0.0364 0.9383 -0.9370 0.0019 -0.091 0.8463 -0.2364 0.6099 
miR-324-5p 
 
13 0.1407 0.6466 0.3147 0.3191 0.1484 0.6286 0.0358 0.9077 0.2253 0.4593 -0.115 0.7074 -0.1926 0.5285 
miR-330-5p 
 
26 -0.0069 0.9735 -0.0577 0.7841 -0.1713 0.4028 -0.0964 0.6393 -0.1610 0.4320 -0.081 0.6950 -0.2693 0.1833 
miR-335-5p 
 
6 -0.2609 0.6175 -0.5508 0.2574 -0.8117 0.0499 -0.7941 0.0592 -0.0580 0.9131 -0.529 0.2801 -0.9412 0.0051 
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miR-34a-5p 
 
8 0.2857 0.4927 0.6667 0.0710 0.3571 0.3851 0.1437 0.7342 0.2619 0.5309 0.024 0.9554 -0.2381 0.5702 
miR-34c-5p 
 
13 0.1022 0.7397 0.3636 0.2453 0.0385 0.9007 0.1515 0.6212 -0.0165 0.9574 -0.085 0.7818 -0.220 0.4700 
miR-361-5p 
 
5 0.3000 0.6238 -0.1000 0.8729 0.3000 0.6238 -0.1000 0.8729 0.6000 0.2848 -0.800 0.1041 -1.000 <0.0001 
miR-370-3p 
 
6 -0.0290 0.9565 0.2609 0.6175 -0.1160 0.8268 0.0294 0.9559 0.0580 0.9131 -0.294 0.5715 -0.118 0.8243 
miR-375 
 
7 0.2857 0.5345 0.5000 0.2532 0.3571 0.4316 0.2703 0.5577 0.2143 0.6445 0.214 0.6445 -0.607 0.1482 
miR-377-3p 
 
8 0.2515 0.5479 0.5270 0.1796 0.1796 0.6703 0.2289 0.5855 0.0120 0.9775 0.216 0.6081 -0.331 0.4227 
miR-380-5p 
 
7 0.7143 0.0713 0.3214 0.4821 0.5000 0.2532 -0.1982 0.6701 0.7857 0.0362 0.000 1.0000 -0.393 0.3833 
miR-381-3p 
 
7 -0.6847 0.0897 -0.6487 0.1150 -0.7928 0.0334 -0.5273 0.2239 -0.6847 0.0897 -0.418 0.3505 -0.745 0.0544 
miR-382-5p 
 
36 -0.2623 0.1223 -0.1213 0.4876 -0.1740 0.3101 -0.0417 0.8092 -0.2525 0.1373 0.121 0.4818 0.107 0.5348 
miR-424-5p 
 
6 -0.0290 0.9565 -0.4928 0.3206 -0.5508 0.2574 -0.4928 0.3206 0.1449 0.7841 0.294 0.5715 0.235 0.6536 
miR-433-3p 
 
8 0.4551 0.2572 -0.1916 0.6494 0.0120 0.9775 -0.2892 0.4873 0.3234 0.4346 -0.205 0.6266 -0.904 0.0021 
miR-4458 
 
6 -0.4928 0.3206 -0.1449 0.7841 -0.5218 0.2883 -0.4706 0.3462 -0.8697 0.0244 0.118 0.8243 -0.353 0.4926 
miR-4500 
 
5 0.4000 0.5046 0.2000 0.7471 0.4000 0.5046 0.2000 0.7471 0.3000 0.6238 0.100 0.8729 -0.500 0.3910 
miR-451a 
 
27 -0.2171 0.2768 0.0126 0.9511 -0.020 0.9230 0.0076 0.9699 0.1258 0.5319 0.046 0.8215 0.276 0.1635 
miR-490-3p 
 
11 -0.3235 0.3319 0.3909 0.2345 -0.055 0.8734 0.1458 0.6689 -0.5364 0.0890 -0.109 0.7490 -0.419 0.1994 
miR-542-3p 
 
32 -0.0136 0.9411 0.0319 0.8649 -0.063 0.7302 0.0202 0.9128 -0.0532 0.7726 0.0479 0.7947 -0.030 0.8693 
miR-7-5p 
 
5 0.1000 0.8729 -0.7000 0.1881 -1.000 0.0001 -0.9747 0.0048 0.3000 0.6238 -0.3000 0.6238 -0.700 0.1881 
miR-96-5p 
 
6 -0.4928 0.3206 -0.1449 0.7841 -0.522 0.2883 -0.4706 0.3462 -0.8697 0.0244 0.1176 0.8243 -0.353 0.4926 
miR-99b-5p 
 
35 -0.0058 0.9738 0.3036 0.0809 0.277 0.1066 0.2988 0.0812 -0.0022 0.9898 0.1521 0.3831 0.085 0.6258 
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Table 3.4: Correlations of Clinical Characteristics and expressed miRNAs 
 
  FBG (mmol/L) 2 HRs Post Glucose 
(mmol/L) 
HbA1c (%) Fasting Insulin  
(mIU/L) 
2 HRs Post Insulin 
(mIU/L) 
Trigs (mmol/L) 
miRNA Number R P-value R P-value R P-value R P-value R P-value R P-value 
let-7i-5p 
 
25 -0.2941 0.1535 -0.4287 0.0366 -0.3079 0.1343 0.011 0.9598 0.1206 0.5837 -0.3555 0.0812 
miR-103a-3p 
 
7 0.2703 0.5577 0.1261 0.7876 0.2703 0.5577 -0.342 0.4523 -0.3063 0.5040 -0.6307 0.1289 
miR-125a-5p 
 
7 0.5000 0.2532 -0.2857 0.5345 0.0357 0.9394 0.200 0.7040 0.0714 0.8790 -0.7500 0.0522 
miR-125b-5p 
 
26 -0.1868 0.3608 -0.2423 0.2432 -0.1760 0.3897 0.369 0.0698 0.4687 0.0209 0.1611 0.4319 
miR-126-5p 
 
20 -0.1995 0.3991 -0.4509 0.0527 -0.2123 0.3687 -0.067 0.7862 0.2012 0.4233 -0.1534 0.5184 
miR-129-2-3p 
 
6 -0.1160 0.8268 -0.0580 0.9131 -0.1160 0.8268 0.580 0.2278 0.2319 0.6584 0.8117 0.0499 
miR-129-5p 
 
20 -0.1694 0.4753 -0.2541 0.2796 -0.0836 0.7261 0.428 0.0672 0.5842 0.0086 -0.0173 0.9423 
miR-130a-3p 
 
8 -0.3810 0.3518 -0.6190 0.1017 -0.6905 0.0580 -0.143 0.7599 0.4286 0.2894 -0.5952 0.1195 
miR-130b-3p 
 
7 -0.8469 0.0162 -0.9550 0.0008 -0.9550 0.0008 -0.145 0.7841 0.7027 0.0782 -0.5946 0.1591 
miR-135b-5p 
 
5 -0.6000 0.2848 -0.1000 0.8729 -0.6000 0.2848 -1.000 0.0001 -0.5000 0.3910 -0.8000 0.1041 
miR-143-3p 
 
23 -0.2731 0.2074 -0.3902 0.0726 -0.2801 0.1956 0.103 0.6470 0.2325 0.3106 -0.1156 0.5993 
miR-146a-5p 
 
21 -0.4595 0.0361 -0.4902 0.0282 -0.3909 0.0798 0.114 0.6334 0.4053 0.0852 -0.2118 0.3568 
miR-152-3p 
 
9 0.1167 0.7650 0.2000 0.6059 0.2167 0.5755 -0.262 0.5309 -0.0333 0.9322 -0.1500 0.7001 
miR-184 6 0.4058 0.4247 0.5798 0.2278 0.4058 0.4247 -0.6088 0.1997 -0.8117 0.0499 -0.2319 0.6584 
miR-194-5p 
 
7 -0.0714 0.8790 -0.3214 0.4821 -0.2857 0.5345 0.0357 0.9394 0.5000 0.2532 -0.4286 0.3374 
miR-195-5p 
 
7 -0.3214 0.4821 -0.6429 0.1194 -0.4643 0.2939 0.5000 0.2532 0.8571 0.0137 0.0357 0.9394 
miR-196-5p 
 
8 -0.2619 0.5309 -0.6190 0.1017 -0.5952 0.1195 0.3571 0.4316 0.5952 0.1195 -0.2857 0.4927 
miR-199a-5p 
 
7 -0.1429 0.7599 -0.0357 0.9394 -0.2857 0.5345 0.0357 0.9394 0.2857 0.5345 0.1429 0.7599 
miR-19a-3p 
 
7 0.2143 0.6445 0.0000 1.0000 0.0714 0.8790 0.0714 0.8790 0.1071 0.8192 -0.3929 0.3833 
miR-200a-3p 
 
20 -0.4622 0.0402 -0.5667 0.0114 -0.4223 0.0636 0.0088 0.9716 0.3540 0.1496 -0.1918 0.4179 
miR-206 
 
6 -0.0857 0.8717 0.1429 0.7872 -0.0857 0.8717 -0.7143 0.1108 -0.3714 0.4685 -0.4286 0.3965 
miR-212-3p 
 
5 -0.7000 0.1881 -0.5000 0.3910 -0.7000 0.1881 -0.6000 0.2848 0.2000 0.7471 -0.1000 0.8729 
miR-214-3p 
 
7 -0.2857 0.5345 -0.3214 0.4821 -0.6786 0.0938 -0.2000 0.7040 0.2500 0.5887 -0.4643 0.2939 
miR-24-3p 
 
7 0.0000 1.0000 -0.2857 0.5345 -0.1071 0.8192 0.7500 0.0522 0.7143 0.0713 0.3571 0.4316 
miR-27a-3p 
 
5 -0.5000 0.3910 -0.7000 0.1881 -0.7000 0.1881 0.1000 0.8729 0.5000 0.3910 -0.4000 0.5046 
miR-27b-3p 
 
6 -0.3714 0.4685 -0.1429 0.7872 -0.6000 0.2080 -0.1429 0.7872 0.4857 0.3287 0.086 0.8717 
miR-296-5p 
 
8 -0.3713 0.3652 -0.3234 0.4346 -0.5389 0.1681 0.0120 0.9775 0.5389 0.1681 -0.168 0.6915 
miR-29b-3p 
 
7 -0.5946 0.1591 -0.6667 0.1019 -0.7748 0.0408 0.0290 0.9565 0.5225 0.2289 -0.450 0.3104 
miR-29c-3p 
 
5 -0.1000 0.8729 -0.6000 0.2848 -0.5000 0.3910 -0.2000 0.8000 -0.1000 0.8729 -1.000 0.0001 
miR-30a-5p 
 
6 0.2319 0.6584 0.1160 0.8268 0.2319 0.6584 0.0290 0.9565 -0.1160 0.8268 -0.464 0.3542 
miR-30c-5p 
 
6 0.1160 0.8268 -0.0580 0.9131 0.1160 0.8268 -0.0870 0.8699 -0.0580 0.9131 -0.638 0.1731 
miR-320b 
 
6 -0.6377 0.1731 -0.2899 0.5774 -0.6377 0.1731 -0.6667 0.1481 -0.0580 0.9131 -0.638 0.1731 
miR-324-3p 
 
7 -0.4144 0.3553 -0.1261 0.7876 -0.1622 0.7283 0.4638 0.3542 0.5946 0.1591 0.721 0.0676 
miR-324-5p 
 
13 -0.2418 0.4262 -0.5245 0.0800 -0.3516 0.2387 0.0140 0.9656 0.2308 0.4705 -0.242 0.4262 
miR-330-5p 
 
26 -0.4330 0.0271 -0.4500 0.0240 -0.4753 0.0141 -0.0400 0.8494 0.3226 0.1242 -0.185 0.3655 
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miR-335-5p 
 
6 -0.8117 0.0499 -0.5218 0.2883 -0.8117 0.0499 -0.5218 0.2883 0.3479 0.4993 -0.203 0.6998 
miR-34a-5p 
 
8 -0.0952 0.8225 -0.6190 0.1017 -0.4048 0.3199 0.6429 0.1194 0.6429 0.0856 0.000 1.0000 
miR-34c-5p 
 
13 -0.3462 0.2466 -0.5245 0.0800 -0.3714 0.2115 0.0629 0.8459 -0.1329 0.6806 -0.302 0.3156 
miR-361-5p 
 
5 -0.1000 0.8729 0.0000 1.0000 -0.1000 0.8729 -0.1000 0.8729 -0.1000 0.8729 -0.300 0.6238 
miR-370-3p 
 
6 0.1160 0.8268 -0.0580 0.9131 0.1160 0.8268 0.4058 0.4247 0.1160 0.8268 0.3769 0.4615 
miR-375 
 
7 -0.2143 0.6445 -0.3571 0.4316 -0.3214 0.4821 0.6429 0.1194 0.7857 0.0362 0.5000 0.2532 
miR-377-3p 
 
8 -0.0240 0.9551 -0.3473 0.3993 -0.1916 0.6494 0.7066 0.0501 0.7545 0.0305 0.4431 0.2715 
miR-380-5p 
 
7 0.3214 0.4821 -0.0714 0.8790 -0.1429 0.7599 0.0286 0.9572 0.0000 1.0000 -0.4643 0.2939 
miR-381-3p 
 
7 -0.7748 0.0408 -0.1261 0.7876 -0.4505 0.3104 -0.2319 0.6584 0.4144 0.3553 0.4685 0.2890 
miR-382-5p 
 
36 -0.2504 0.1408 -0.3045 0.0753 -0.4003 0.0156 -0.1133 0.5169 0.0000 1.0000 -0.1124 0.5140 
miR-424-5p 
 
6 -0.1160 0.8268 0.2899 0.5774 -0.1160 0.8268 -0.8407 0.0361 -0.6377 0.1731 -0.2899 0.5774 
miR-433-3p 
 
8 -0.2515 0.5479 -0.2036 0.6287 -0.4192 0.3013 0.0599 0.8880 0.4431 0.2715 -0.2156 0.6081 
miR-4458 
 
6 -0.8117 0.0499 -0.8117 0.0499 -0.8117 0.0499 0.2319 0.6584 0.9276 0.0077 0.6088 0.1997 
miR-4500 
 
5 -0.3000 0.6238 0.0000 1.0000 -0.3000 0.6238 0.2000 0.7471 0.2000 0.7471 0.6000 0.2848 
miR-451a 
 
27 -0.2233 0.2629 -0.2695 0.1831 -0.2899 0.1424 0.0133 0.9484 0.1423 0.4974 0.0046 0.9819 
miR-490-3p 
 
11 -0.5182 0.1025 -0.7909 0.0037 -0.6105 0.0461 0.2000 0.5554 0.3576 0.3104 -0.2455 0.4669 
miR-542-3p 
 
32 -0.1482 0.4181 -0.2472 0.1800 -0.1857 0.3090 0.0990 0.5962 0.1483 0.4427 -0.0356 0.8467 
miR-7-5p 
 
5 -0.7000 0.1881 -0.2000 0.7471 -0.7000 0.1881 -0.4000 0.5046 0.1000 0.8729 0.0000 1.0000 
miR-96-5p 
 
6 -0.8117 0.0499 -0.8117 0.0499 -0.8117 0.0499 0.2319 0.6584 0.9276 0.0077 0.6088 0.1997 
miR-99b-5p 
 
35 -0.1033 0.5548 -0.2352 0.1806 -0.0017 0.9923 -0.0918 0.6054 -0.1342 0.4641 -0.0430 0.8062 
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Table 3.5: Correlations of clinical characteristics and expressed miRNAs 
  LDL-Chol (mmol/L) HDL-Chol (mmol/L) Total Chol (mmol/L) Chol/HDL ratio CRP (mg/L) Cotinine (ng/mL) Gamma GT-S (IU/L) 
miRNA Number R P-value R P-value R P-value R P-value R P-value R P-value R P-value 
let-7i-5p 
 
25 -0.3620 0.0753 0.1650 0.4307 -0.3849 0.0574 -0.3722 0.0733 -0.0185 0.9302 -0.1270 0.5451 -0.1302 0.5350 
miR-103a-3p 
 
7 0.2883 0.5307 -0.1636 0.7259 0.2883 0.5307 0.5218 0.2883 0.0000 1.0000 -0.3371 0.4597 0.4144 0.3553 
miR-125a-5p 
 
7 0.0357 0.9394 -0.7207 0.0676 0.2883 0.5307 0.3714 0.4685 0.4643 0.2939 -0.0891 0.8494 -0.3214 0.4821 
miR-125b-5p 
 
26 0.0445 0.8289 -0.4299 0.0284 -0.0315 0.8787 0.3010 0.1437 0.4632 0.0172 0.2615 0.1968 -0.0733 0.7221 
miR-126-5p 
 
20 -0.1167 0.6242 -0.2555 0.2770 -0.2611 0.2662 0.0897 0.7151 0.1459 0.5395 -0.0900 0.7061 -0.4000 0.0806 
miR-129-2-3p 
 
6 0.6957 0.1248 0.1739 0.7417 0.6957 0.1248 0.1160 0.8268 -0.1739 0.7417 0.0000 1.0000 0.2029 0.6998 
miR-129-5p 
 
20 -0.0301 0.8997 -0.3132 0.1787 -0.2152 0.3622 0.1185 0.6289 0.4060 0.0757 0.3021 0.1955 -0.0806 0.7355 
miR-130a-3p 
 
8 -0.2381 0.5702 -0.4791 0.2297 0.0000 1.0000 0.6071 0.1482 -0.0714 0.8665 -0.2182 0.6036 -0.5000 0.2070 
miR-130b-3p 
 
7 -0.3063 0.5040 -0.5455 0.2054 -0.1982 0.6701 0.5798 0.2278 0.1441 0.7578 -0.3371 0.4597 -0.5766 0.1754 
miR-135b-5p 
 
5 -0.3000 0.6238 0.5643 0.3217 -0.3000 0.6238 -0.2000 0.8000 -0.7000 0.1881 -0.7071 0.1817 -0.3000 0.6238 
miR-143-3p 
 
23 -0.1177 0.5926 -0.2833 0.1902 -0.1933 0.3768 0.0781 0.7299 0.3113 0.1483 0.2501 0.2498 -0.0015 0.9946 
miR-146a-5p 
 
21 -0.0825 0.7220 -0.3101 0.1713 -0.1677 0.4675 0.1220 0.6083 0.2519 0.2706 0.2581 0.2586 -0.1028 0.6574 
miR-152-3p 
 
9 0.2500 0.5165 0.2762 0.4720 0.2678 0.4860 -0.0714 0.8665 -0.6167 0.0769 -0.2079 0.5914 0.1667 0.6682 
miR-184 6 -0.1449 0.7841 0.3529 0.4926 -0.1449 0.7841 -0.5643 0.3217 -0.1449 0.7841 -0.0171 0.9743 -0.1449 0.7841 
miR-194-5p 
 
7 0.2857 0.5345 -0.3604 0.4271 0.3964 0.3786 0.7143 0.1108 -0.4286 0.3374 -0.1336 0.7752 0.0357 0.9394 
miR-195-5p 
 
7 0.0357 0.9394 -0.6847 0.0897 0.1081 0.8175 0.7143 0.1108 -0.0357 0.9394 0.2227 0.6312 0.2500 0.5887 
miR-196-5p 
 
8 -0.1905 0.6514 -0.6467 0.0831 0.0120 0.9775 0.5714 0.1802 0.2143 0.6103 -0.0779 0.8545 -0.2143 0.6103 
miR-199a-5p 
 
7 0.2143 0.6445 0.0360 0.9389 0.2883 0.5307 0.1429 0.7872 -0.2857 0.5345 -0.4009 0.3728 0.3214 0.4821 
miR-19a-3p 
 
7 0.2857 0.5345 -0.3424 0.4523 0.3604 0.4271 0.6000 0.2080 0.1429 0.7599 -0.4009 0.3728 0.6429 0.1194 
miR-200a-3p 
 
20 -0.0632 0.7911 -0.1379 0.5620 -0.1783 0.4519 -0.0229 0.9260 0.0902 0.7052 0.0772 0.7462 -0.2829 0.2268 
miR-206 
 
6 0.5429 0.2657 0.7247 0.1032 0.5429 0.2657 -0.3000 0.6238 -0.8286 0.0416 -0.6547 0.1583 -0.4286 0.3965 
miR-212-3p 
 
5 0.3000 0.6238 0.6000 0.2848 0.3000 0.6238 0.2000 0.8000 -0.9000 0.0374 -0.3536 0.5594 -0.4000 0.5046 
miR-214-3p 
 
7 -0.6071 0.1482 -0.4324 0.3325 -0.3063 0.5040 0.2000 0.7040 0.0714 0.8790 -0.2673 0.5623 -0.6429 0.1194 
miR-24-3p 
 
7 -0.0357 0.9394 -0.6667 0.1019 0.0180 0.9694 0.4286 0.3965 0.2500 0.5887 0.4009 0.3728 0.2857 0.5345 
miR-27a-3p 
 
5 -0.3000 0.6238 -0.4617 0.4338 -0.2052 0.7406 0.8000 0.2000 0.2000 0.7471 -0.1118 0.8579 0.2000 0.7471 
miR-27b-3p 
 
6 0.1429 0.7872 0.1160 0.8268 0.2609 0.6175 -0.1000 0.8729 -0.8286 0.0416 -0.3381 0.5122 -0.2571 0.6228 
miR-296-5p 
 
8 0.1317 0.7558 -0.0482 0.9098 0.2169 0.6059 0.4144 0.3553 -0.5389 0.1681 -0.4116 0.3110 -0.2036 0.6287 
miR-29b-3p 
 
7 -0.1622 0.7283 -0.2727 0.5540 -0.0180 0.9694 0.3479 0.4993 0.1802 0.6990 -0.5169 0.2349 -0.4324 0.3325 
miR-29c-3p 
 
5 0.1000 0.8729 -0.5643 0.3217 0.5000 0.3910 0.8000 0.2000 0.4000 0.5046 -0.7071 0.1817 -0.3000 0.6238 
miR-30a-5p 
 
6 0.5508 0.2574 -0.0294 0.9559 0.5508 0.2574 0.8721 0.0539 0.0290 0.9565 -0.6002 0.2078 0.5508 0.2574 
miR-30c-5p 
 
6 0.4928 0.3206 -0.1765 0.7380 0.4928 0.3206 0.9747 0.0048 -0.0290 0.9565 -0.6002 0.2078 0.4928 0.3206 
miR-320b 
 
6 -0.2609 0.6175 0.4412 0.3812 -0.2609 0.6175 -0.0513 0.9347 -0.6667 0.1481 -0.7717 0.0722 -0.2609 0.6175 
miR-324-3p 
 
7 0.3604 0.4271 0.0727 0.8769 0.1441 0.7578 0.1160 0.8268 -0.4865 0.2682 0.3371 0.4597 0.3604 0.4271 
miR-324-5p 
 
13 0.1843 0.5466 -0.1926 0.5285 0.1926 0.5285 0.3328 0.2906 -0.1209 0.6940 -0.3258 0.2774 -0.3439 0.2500 
miR-330-5p 
 
26 -0.2387 0.2402 -0.1413 0.4912 -0.2552 0.2083 -0.0146 0.9446 0.1501 0.4643 0.1484 0.4692 -0.0442 0.8302 
miR-335-5p 
 
6 0.2319 0.6584 0.4706 0.3462 0.2319 0.6584 0.1539 0.8048 -0.8117 0.0499 -0.7717 0.0722 -0.0870 0.8699 
miR-34a-5p 
 
8 0.2381 0.5702 -0.6108 0.1077 0.3473 0.3993 0.6071 0.1482 0.3810 0.3518 -0.0156 0.9708 0.0476 0.9108 
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miR-34c-5p 
 
13 0.0824 0.7890 -0.2146 0.4814 0.1018 0.7407 0.0455 0.8883 -0.0330 0.9149 0.0564 0.8548 -0.3246 0.2792 
miR-361-5p 
 
5 0.2000 0.7471 0.0513 0.9347 0.2000 0.7471 0.6000 0.4000 -0.1000 0.8729 -0.7071 0.1817 0.6000 0.2848 
miR-370-3p 
 
6 0.6957 0.1248 0.0000 1.0000 0.6957 0.1248 0.3591 0.5528 -0.1160 0.8268 0.0514 0.9229 0.3769 0.4615 
miR-375 
 
7 -0.0714 0.8790 -0.4685 0.2890 -0.0180 0.9694 0.2571 0.6228 -0.0357 0.9394 0.4009 0.3728 0.0357 0.9394 
miR-377-3p 
 
8 0.1078 0.7995 -0.5602 0.1487 0.1386 0.7435 0.4286 0.3374 0.1078 0.7995 0.5351 0.1718 0.1198 0.7776 
miR-380-5p 
 
7 0.0000 1.0000 -0.3424 0.4523 0.2883 0.5307 -0.0857 0.8717 0.2143 0.6445 -0.4009 0.3728 -0.2143 0.6445 
miR-381-3p 
 
7 0.2523 0.5852 0.4909 0.2633 0.1441 0.7578 -0.1739 0.7417 -0.8469 0.0162 -0.2023 0.6636 0.2523 0.5852 
miR-382-5p 
 
36 -0.2193 0.1988 0.0490 0.7765 -0.1500 0.3825 -0.1525 0.3817 0.0891 0.6055 0.1903 0.2664 0.0057 0.9738 
miR-424-5p 
 
6 -0.4928 0.3206 0.5882 0.2194 -0.4928 0.3206 -0.8721 0.0539 -0.4928 0.3206 -0.1886 0.7204 -0.4928 0.3206 
miR-433-3p 
 
8 0.0838 0.8435 -0.0723 0.8649 0.1687 0.6897 0.3424 0.4523 -0.4192 0.3013 -0.4116 0.3110 -0.1557 0.7128 
miR-4458 
 
6 0.2319 0.6584 -0.0882 0.8680 0.2319 0.6584 0.1539 0.8048 -0.5218 0.2883 0.0171 0.9743 -0.2029 0.6998 
miR-4500 
 
5 -0.4000 0.5046 0.1539 0.8048 -0.4000 0.5046 0.0000 1.0000 0.2000 0.7471 0.0000 1.0000 0.3000 0.6238 
miR-451a 
 
27 -0.1346 0.5034 -0.0086 0.9661 -0.1277 0.5257 -0.0613 0.7662 0.1667 0.4060 0.3283 0.0945 0.1588 0.4290 
miR-490-3p 
 
11 -0.1468 0.6667 -0.0501 0.8837 -0.2688 0.4242 -0.0182 0.9601 0.1545 0.6500 -0.1053 0.7580 -0.3235 0.3319 
miR-542-3p 
 
32 -0.1485 0.4173 -0.0800 0.6636 -0.1522 0.4056 0.0242 0.8971 0.2009 0.2703 0.0990 0.5899 -0.0198 0.9142 
miR-7-5p 
 
5 0.4000 0.5046 0.6669 0.2189 0.4000 0.5046 -0.4000 0.6000 -1.000 0.0001 -0.7071 0.1817 -0.2000 0.7471 
miR-96-5p 
 
6 0.2319 0.6584 -0.0882 0.8680 0.2319 0.6584 0.1539 0.8048 -0.5218 0.2883 0.0171 0.9743 -0.2029 0.6998 
miR-99b-5p 
 
35 0.0488 0.7806 -0.2389 0.1670 -0.0046 0.9790 0.2621 0.1343 0.0188 0.9148 -0.1637 0.3474 -0.3908 0.0203 
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CHAPTER 4: DISCUSSION 
 
MicroRNAs are receiving increased attention as potential biomarkers of many disease 
conditions including glucose intolerance and studies have reported the detection of miRNAs 
in blood and other body fluids in relation to pathophysiological status (Chen et al., 2008; 
Mitchell et al., 2008; Gilad et al., 2008; Weber et al., 2010 and Izzotti et al., 2018). Despite 
growing support for miRNAs as potential biomarkers for glucose intolerance globally, such 
evidence is lacking in South Africa. Previous studies from our laboratory have shown that the 
prevalence of glucose intolerance in the mixed ancestry cohort of Bellville South, South Africa 
is increasing rapidly (Erasmus et al., 2012 and Matsha et al., 2013) and majority of those with 
diabetes were undiagnosed.  
 
Successful and accurate identification of people with preDM, who are likely to progress to the 
full stage of the disease, is the actual means to eradicate DM and its complications (Matsha 
et al., 2018). Until recently, the diagnosis of preDM and DM for instance, requires individuals 
to be subjected to the cumbersome oral glucose overload and measurement of blood glucose 
post 2 hours (Ko et al., 1998; Alberti and Zimmet 1988). As a result, individuals with this 
category of preDM largely remain undiagnosed. However, the emerging evidence for the role 
of miRNAs in the development of human diseases including diabetes is encouraging. In the 
development of diabetes, miRNAs have been reported to regulate metabolism, adipocyte 
differentiation, pancreatic development, β-cell mass, insulin biosynthesis, secretion and 
signaling (Poy et al., 2004; Uchida et al 2006; Hausser et al., 2011; Zhu et al., 2011 and Gu 
et al.,2016) underscoring their important role in the early diagnosis, pathogenesis and 
treatment of diabetes. 
 
Some of the dysregulated miRNAs found in our study corroborate findings of many other 
studies that have aimed to characterize miRNAs in different tissue types of individuals with 
DM and/or preDM (He et al., 2017). A recent systematic study of dysregulated miRNAs in 
T2DM identified a total of 158 dysregulated miRNAs in adipose, islet, skeletal muscle, whole 
blood, PBMC, plasma and serum (He et al., 2017). In our study, 84 circulating miRNAs were 
investigated in the serum of 36 randomly picked mixed ancestry participants (women) in three 
groups according to their glycemic status’ (controls, preDM and DM) to ascertain their 
biomarker properties in glucose intolerance. Differential expression was observed in 12 
miRNAs across all groups, 3 miRNAs in the control and DM groups and 39 miRNAs only in 
one group (DM group). Table 4.1 shows the summary of micro RNAs expressed in present 
study compared to other studies. 
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Table 4.1: A summary of micro RNAs expressed in present study compared to other 
studies 
miRNAs Study Sample type Exp Change  Disease state Reference 
let-7i-5p PS Serum up-regulated DM PS 
 PS Serum up-regulated preDM PS 
 OS Serum down-regulated DM Yang et al., 2014 
miR-125b-5p PS Serum up-regulated DM PS 
 PS Serum down-regulated preDM PS 
 OS Serum up-regulated DM Wang et al., 2016 
 OS Adipose up-regulated DM Klöting et al., 2009 
 OS Plasma down-regulated DM Ortega et al., 2014 
miR-126b-5p PS Serum up-regulated DM PS 
 PS Serum up-regulated preDM PS 
 OS WB down-regulated DM Karolina et al.,2011 
 OS PBMC down-regulated DM Meng et al.,2012 
 OS Plasma up-regulated DM Lu et al.,2014 
miR-129b-5p PS Serum up-regulated DM PS 
 PS Serum down-regulated preDM PS 
 OS Islets up-regulated DM Locke et al., 2014 
miR-143-3p PS Serum up-regulated DM PS 
 OS Adipose up-regulated DM Xie et al.,2009 
miR-146a-5p PS Serum up-regulated DM PS 
 PS Serum down-regulated preDM PS 
 OS Plasma up-regulated DM Heilmeier et al.,2016 
 OS Serum down-regulated DM Yang et al., 2014 
miR-200a-3p PS Serum up-regulated DM PS 
 PS Serum down-regulated preDM PS 
 OS Adipose up-regulated DM Zhao et al.,2009 
miR-330-5p PS Serum up-regulated DM PS 
 OS Liver cells down-regulated DM Zhao et al.,2009 
miR-382-5p PS Serum up-regulated DM PS 
 OS Bone cells up-regulated DM Heilmeier et al.,2016 
miR-451a PS Serum up-regulated DM PS 
 PS Serum down-regulated preDM PS 
 OS SM up-regulated DM Yuqing et al.,2017 
miR-542-3p PS Serum up-regulated DM PS 
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 PS Serum down-regulated preDM PS 
 OS ESSC up-regulated DM Yuqing et al.,2017 
miR-99b-5p PS Serum no change DM PS 
 PS Serum no change preDM PS 
 OS  up-regulated DM Paramasivam 2015 
Key:  PS = Present study 
OS = Other Studies 
WB = White blood 
PBMC = Peripheral blood mononuclear cells 
SM = Skeletal muscles 
Islet = Islets of langerhans 
ESSC = Endometrial Stromal Stem Cells  
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4.1. MicroRNAs expressed in control, preDM and DM 
 
MicroRNA expression is affected by a number of factors. In this study some microRNAs 
showed significant relationships with one or more glycaemic parameters (FBG, 2HRs post 
glucose, HbA1C, FBI and 2HRs post insulin). MiR-125b-5p and miR-129b-5p were expressed 
across all 3 groups and were positively correlated with 2HRs post insulin (mIU/L). Thus, their 
expression through all groups, indicates they are normally found circulating in serum, but only 
get altered with changes in the insulin levels, hence making them good markers in the insulin 
production/proliferation pathway. Furthermore, miR-125b-5p was also positively correlated 
with CRP (mg/L), a marker for inflammation. Inflammation has been shown to precede the 
development of diabesity (Herrera et al., 2009). Elevated levels of inflammatory cytokines 
predict future weight gain, and infusion of inflammatory cytokines into healthy, normal weight 
participants caused insulin resistance (Herrera et al., 2009). In this study, miR-125b-5p was 
up-regulated in DM as seen in Table 4.1. Up-regulation of miR-125b-5p in the liver of 
hyperglycemic participants results in a proinflammatory diabetic phenotype in vascular smooth 
muscle cells (Herrera et al., 2009).  
 
MiR-146a-5p, miR-200a-3p and miR-330-5p were expressed through all 3 groups and all 
inversely correlated with both FBG (mmol/L) and 2HRs Post Glucose. Only miR-330-5p 
showed a negative correlation with HbA1C as well. Their expression through all groups 
indicates that they are normally found circulating in serum, but only get altered with changes 
in the glucose levels. Therefore, they can serve as good markers to identify early development 
of hyper-glycaemia. MiR-146a-5p has been reported to contribute to increased apoptosis of 
β-cells expression induced by cytokines and sodium palmitate (Roggli et al., 2010). MiR-200a-
3p has equally been reported to be up-regulated in the adipose tissue of diabetic participants 
(Zhao et al., 2009). Also, miR-330-5p was reported to be down-regulated in the liver cells of 
diabetic participants (Zhao et al., 2009). miRNAs regulate insulin resistance in liver and 
hepatocytes and this is well documented by many studies. Up-regulation of miRNA in the livers 
of diabetic participants (Jordan et al., 2011) and obese participants (Takanabe et al., 2008) 
has been observed. Further study has shown that miRNA down-regulates Oxysterol-binding 
protein-related protein 8 (Orp8), and inturn impairs the ability of insulin to induce the activation 
of Protein kinase B (PKB) signaling, a central signaling node of insulin action to induce glucose 
metabolism (Jordan et al., 2011). 
This implies each of these miRNAs affect different pathways leading to glucose intolerance 
and is differentially expressed in different samples. 
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MiR-382-5p was expressed through all groups and only inversely correlated with HbA1C. Its 
expression through all groups indicates that it is normally found circulating in serum, but only 
gets altered with changes in the HbA1C levels. Even though miR-451a was expressed through 
all groups, it was expressed more in DM than the control as compared to the preDM (Figure 
4.1). It also did not correlate with any clinical characteristics. Furthermore, it is down-regulated 
in preDM while up-regulated in DM (Figure 4.1). MiR-451a was found to be up-regulated in 
serum and skeletal muscles in T2DM (Yuqing et al., 2017). MiR-382-5p has not been reported 
to be directly related to DM, but it has been found increased in diabetic women with 
osteoporosis (Heilmeier et al., 2016), but interestingly, in this study miR-382-5p shows direct 
relationships with dysglycemia. 
 
MiR-126-5p, miR-143-3p, miR-542-3p and miR-99b-5p were expressed in all groups, but 
showed no correlation with any of the clinical characteristics. MiR-99b-5p was identified to be 
equally expressed through all groups (Table 4.1). There was evidently no change in the 
expression levels of miR-99b-5p both in the controls and the disglycemic states (Figure 4.1). 
Therefore miR-99b-5p may serve as a housekeeping gene in further studies concerning 
glucose intolerance. Contrary to this study, an Asian Indian study reported miR-99b-5p to be 
slightly up-regulated in DM participants (Paramasivam et al., 2015). This discrepancy in the 
two studies might be as a result of the different methods or apparatus’ used in the different 
experiments or may be ethnic-specific.  
 
MiR-542-3p has received little attention in relation to metabolic disorders, but it has been 
reported to have potential as a biomarker or therapeutic target in endometriosis (Yuqing et al., 
2017). The endometrium has been reported to provide an easily accessible, renewable, and 
immunologically identical source of stem cells with potential therapeutic applications in 
diabetes (Yuqing et al., 2017). Thus implying an up-regulation of miR-542-3p could encourage 
the differentiation of normal human endometrial stromal stem cells (ESSC) into insulin 
secreting cells which could actually serve as a remedy for DM, especially T1DM (Shamima et 
al., 2017). 
Though in this study miR-143-3p was up-regulated in DM but not affected in preDM (Figure 
4.1), it has been reported to participate in adipocyte differentiation, it is also induced in 
adipogenesis and down-regulated in obesity (Xie et al., 2009). MiR-126-5p was up-regulated 
in both DM and preDM and it is expressed a little bit more in DM than in preDM (Figure 4.1). 
It has been reported to be expressed during pancreatic development and up-regulated in 
skeletal muscles (Li et al., 2009). Most recently, findings of up-regulation of miR-126 in preDM 
versus screen-detected DM most probably pointed towards a cascading reduction with respect 
  44 
 
to DM related complications suggesting a potential role for miR-126 in distinguishing preDM 
from DM (Matsha et al., 2018).  
Let-7i-5p was expressed through all groups and was inversely correlated with 2HRs Post 
Glucose (mmol/L). It was expressed more in preDM than in DM (Table 4.1). The let-7 family 
is ubiquitously expressed and a global knockdown of let-7 protects against glucose intolerance 
(Frost and Olson, 2011), whereas global and pancreas-specific over-expression impair 
glucose tolerance by decreasing glucose-stimulated insulin-secretion (Frost and Olson, 2011). 
In addition, transgenic overexpression of let-7 causes glucose intolerance associated with 
decreased muscle specific expression of several proteins of the insulin signalling pathway, 
including IRS2 (insulin receptor substrate 2) and the insulin receptor (Zhu et al., 2011). Hence, 
the let-7 family orchestrates diverse aspects of glucose metabolism in different tissues (Zhu 
et al., 2011). This therefore ties with the way let-7i-5p is being expressed in this study, as more 
of it is expressed in preDM than DM, reflecting the ubiquitous nature of the let-7 family. This 
may also reflect a compensatory mechanism that only occurs in prediabetic status, but shuts 
down as the disease progresses to DM stage. 
 
4.2. MicroRNAs expressed in control and DM only 
 
MiR-324-5p, miR-34c-5p and miR-490-3p were expressed in only two groups (control and DM) 
and were as well all up-regulated in DM. Their Ct values indicate that, they can be found in 
little quantities in controls, but only get a little elevated in DM, but not preDM. MiR-490-3p was 
inversely correlated with HbA1c (%) and 2HRS Post Glucose (mmol/L), though up-regulated 
in DM (Table 4.1). Though little has been reported on miR-324-5p, miR-34c-5p and miR-490-
3p and their correlations with metabolic disorders, miR-324-5p has been implicated to be up-
regulated in T1DM and as an early biomarker in T1DM (Erener et al., 2017). MiR-34c-5p was 
validated as significantly highly expressed in circulating monocytes in T2D patients (Baldeón 
et al., 2015). Hence implying that they are found affecting different metabolic pathways and 
could serve as possible biomarkers for dysglycemia. 
 
4.3. MicroRNAs expressed in DM only 
 
Amongst the miRNA’s expressed only in DM, there are some that show strong correlation with 
some clinical parameters. MiR-130b-3p and miR-96-5p were both inversely correlated with 
FBG (mmol/L), 2HRS Post Glucose (mmol/L) and HbA1C (%) but miR-96-5p was equally 
positively correlated with 2HRS Post Insulin (mIU/L). Hence, they could serve as markers 
which can only be found in circulation in DM state. 
MiR-4458 was inversely correlated with FBG (mmol/L), 2HRS Post Glucose (mmol/L), 2HRS 
Post Insulin (mIU/L) as well as WHR. Globally, miR-4458 has received very little attention, 
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especially in studies involving metabolic disorders and particularly glucose intolerance. The 
results in this study show evidence that miR-4458 has a major role to play in glucose 
intolerance as it is well expressed in the DM group and its correlations with glycemic 
parameters. This implies its presence in circulation is indicative of a glucose disorder, 
especially DM. 
 
Furthermore, miR-135b-5p, miR-184, and miR-424-5p were inversely correlated with 2HRS 
Post Insulin (mIU/L), while miR-375 and miR-377 were both positively correlated with 2HRS 
Post Insulin (mIU/L). Previous studies have shown that miR-375 was expressed in pancreatic 
development and regulated insulin secretion in β-cells and increased their death by lipo-
apoptosis, as it regulates cell viability and proliferation (Kloosterman et al., 2007; El et al., 
2008 & Li et al, 2010). Moreover, it was found up-regulated in β-cells of T2D participants and 
its deletion caused severe insulin-deficient diabetes in the participants (Kloosterman et al., 
2007 & Li et al, 2010). MiR-129-2-3p and miR-29c-3p were positively and inversely correlated 
with Trigs (mmol/L) respectively. These miRNAs may have important roles to play in 
adipogenesis, differentiation and/or proliferation. They could either hinder or promote certain 
biochemical pathways.  
 
MiR-7-5p, miR-27b-3p, miR-206, miR-212-3p, miR-335-5p, and miR-381-3p were all inversely 
correlated to CRP (mg/L). These miRNAs may as well have important roles to play in certain 
inflammatory pathways that might be linked to glucose intolerance and its complications. MiR-
335-5p was equally inversely correlated with FBG (mmol/L) but previous findings show  that, 
miR‐335 influenced insulin secretion and miR‐335 overexpression negatively affects insulin 
secretion via the reduction in multiple exocytosis protein targets and impaired priming of insulin 
granule (Wang et al., 2016). 
There was no association between age and miRNA as there was no correlation between the 
age and the miRNAs in this study. Other parameters like WHR, waist (cm) and hip (cm) were 
scarcely correlated with the miRNAs expressed. This might have been as result of the sample 
used, since miRNA expression is also affected by the sample type. 
Smoking, alcohol and gamma GT have shown no association with the miRNA expression as 
well, since there were evidently no significant associations/correlations recorded in our study. 
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Table 4.2: Fold changes and average Ct values of microRNAs expressed through all groups and 
between two groups 
Ct value is inversely proportional to the amount of micro RNA expressed 
Fold changes equal to 1 = No change 
Fold changes greater than 1 = Up-regulation  
Fold changes less than 1 = Down-regulation 
NA = Not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MicroRNA Normal 
group 
Average 
Ct value 
preDM group 
Average Ct 
value 
DM  group 
Average Ct 
value 
preDM/N 
2DD_Ct (fold  
change) 
DM/N 
2DD_Ct (fold  
change) 
DM/preDM2
DD_Ct (fold 
change) 
let-7i-5p 31 28 29 8 4 0.5 
miR-125b-5p 29 31 28 0.25 2 8 
miR-126b-5p 33 32 31 2 4 2 
miR-129b-5p  30 31 29 0.5 2 4 
miR-143-3p 28 28 26 1 4 4 
 miR-146a-5p   31 32 29 0.5 4 8 
miR-200a-3p  32 33 30 0.5 4 8 
miR-330-5p  32 32 30 1 4 4 
miR-382-5p 27 27 26 1 2 2 
miR-451a 30 32 29 0.25 2 8 
miR-542-3p   31 32 30 0.5 2 4 
miR-99b-5p 31 31 31 1 1 1 
miR-324-5p 31 NA 31 NA 2 NA 
miR-34c-5p 32 NA 32 NA 2 NA 
miR-490-3p 34 NA 32 NA 4 NA 
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Fig 4.1: Fold changes of the individual 12 micro RNAs expressed through all three groups 
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4.4. The strengths of the study 
 
RT-PCR was used to evaluate the expression of circulation miRNAs in the serum of participants 
which was a lot less time consuming and less cumbersome as the present day’s routine tests for 
glucose tolerance. 
Furthermore, circulating miRNAs are expressed in the pre-diabetic state, hence paving a way to 
manage diabetes, preventing its progress to diabetes and the complications that come with 
diabetes. 
 
4.5. Weaknesses of the study 
 
RT-PCR is an expensive procedure to be used in a diagnostic laboratory as compared to the 
routine diagnostics tests in the present day’s laboratory; which means it would not be cost-
effective in low-economic countries.  Also, this study was limited to a small population of selected 
females only. 
 
4.6. Future perspectives 
 
Although this study showed that miRNAs were associated with glucose intolerance, prospective, 
longitudinal studies in different populations are required to confirm their potential as special 
biomarkers for T2DM. More so, a study population that comprises of both males and females at 
different ages will shed more light on the biomarker capacities of the circulating miRNAs. 
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CHAPTER 5: CONCLUSION 
 
In conclusion, our results show that circulating miRNAs are associated with glucose intolerance in 
individuals of mixed ancestry descent, despite the limitations eluded earlier on. Our results add to 
the growing body of evidence that circulating miRNAs are associated with glucose intolerance and 
can be detected during pre-diabetes, the asymptomatic stage of T2DM and in T2DM as well. These 
findings support the use of miRNAs as biomarkers for early detection of T2DM. The quick, precise 
and less cumbersome procedure used in this study as compared to the procedures of the current 
diagnostic tests for glucose intolerance previously mentioned, gives it the best standing for the 
diagnosis, prognosis and possibly treatment of T2DM. To our knowledge, this is the first study to 
assess circulating miRNAs in serum as biomarkers for glucose intolerance in the mixed ancestry 
population in South Africa. 
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very important that you are fully satisfied that you clearly understand what this research entails  
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and how you could be involved. Also, your participation is entirely voluntary and you are free to 
decline to participate. If you say no, this will not affect you negatively in any way whatsoever. You 
are also free to withdraw from the study at any point, even if you do agree to take part initially. 
 
This research study has been approved by the ethics Faculty of Health & Wellness Sciences of 
the Cape Peninsula University of Technology and it will be conducted according to international 
and locally accepted ethical guidelines for research, namely the Declaration of Helsinki, and the 
SA Department of Health’s 2004 Guidelines: Ethics in Health Research: Principles, Structures and 
Processes. 
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Genetic material, also called DNA or RNA, is usually obtained from a small blood sample. 
Occasionally genetic material is obtained from other sources such as saliva or biopsy specimens. 
(A biopsy is a tiny piece of tissue that is cut out e.g. from the skin or from a lump, to help your 
doctor make a diagnosis). Genes are found in every cell in the human body. Our genes determine 
what we look like and sometimes what kind of diseases we may be susceptible to. Worldwide, 
researchers in the field of genetics are continuously discovering new information that may be 
of great benefit to future generations and also that may benefit people today, who suffer from 
particular diseases or conditions. 
 
 
 
This research study seeks to address the increasing problem of diabetes and cardiovascular 
diseases such as heart attack and stroke amongst the mixed ancestry or coloured population of 
South Africa. In this study we shall identify people with diabetes and those at high risk of diabetes 
as well as investigate the environmental and genetic risk factors that predispose some 
individuals to the development of diabetes and cardiovascular diseases. Examples of 
environmental factors include body weight, diet, and physical activity. Additionally, this project 
aims to investigate whether oral health is a risk factor for diabetes and cardiovascular diseases. 
In this study we shall investigate whether some individuals have early cardiovascular diseases 
by using an ultrasound machine. This project also aims to collect genetic material (blood) to 
analyze for certain variants and to store excess material for future research. When a large group 
of patients with similar diseases has been collected, meaningful research into the disease 
processes may become possible. 
 
 
 
Our research team has previously conducted a similar research study involving the coloured 
community and found out that more that 18 out of 100 individuals had diabetes but did not know. 
We also found that some of the risk factors associated with diabetes in other populations were not 
necessary the same as those affecting the coloured population of South Africa. You  
 
1.   What is Genetic research? 
2.   What does this particular research study involve? 
3.   Why have you been invited to participate? 
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have therefore been invited to take part in this research study to assist in establishing the risk 
factors for diabetes and cardiovascular diseases affecting the coloured people of South Africa. 
 
 
 
A. You will be requested to provide information about your medical history, family history and 
information on eating, drinking and smoking habits. Completion of the questionnaire will take no 
longer than 30 minutes. 
B. You shall be requested to provide a record of the medication you are currently taking, therefore 
if you are taking chronic medication, you shall be requested to provide this to the research team 
to record the medication. 
C. Measurement such as weight, height, waist and hip will be done. 
D. Fasting Venous Blood (20ml) will be collected thereafter you will be asked to drink a glucose 
solution (glucose content 75g). After two hours another venous blood (10ml) will be collected. The 
blood will be used to determine whether you have diabetes or you are at high risk for developing 
diabetes. 
E. The other tests that will be determined from your blood sample are: Cholesterol, triglycerides, 
creatine levels to assess your kidney function, liver enzymes to assess your liver, and biochemical 
markers for inflammation. 
F. A finger prick blood sample (a drop of blood), to be taken at the same time of the first venous 
blood sample, may also be required from you. The finger prick blood sample will be used to test 
for diabetes or the risk of developing diabetes on a point-of-care test instrument. Researchers 
will compare the finger prick point-of-care diabetes test with that of the send away venous 
blood laboratory test and would be able to establish whether the point-of-care test provides the 
same accurate results as that of the laboratory. Point-of-care testing may in the future be used 
to provide fast and accurate results without the need to send blood away to a laboratory for 
processing. This may be of benefit to people undergoing testing for diabetes as results would be 
available within a few minutes. 
G. The remainder of the blood sample will be used for genetic and future research studies. The 
serum and DNA may be stored for several years until the technology for meaningful analysis 
becomes available. No pharmaceutical agent (medication) will be tested in the study. 
H. For oral health, research  study  personnel  will  extract  wooden  toothpick,  flocked  brush,  
and mouthwash saliva samples from you to test for the presence of Porphyromonas gingivalis as 
an indicator for periodontal disease. Flocked brush and wood toothpick sampling will involve 
inserting devices in the subgingival crevice between the last upper premolar and the first upper  
4.   What procedures will be involved in this research? 
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molar. The device will sweep down the anterior surface of the first upper molar with the direction 
of motion away from the gum to minimize any potential discomfort. Mouthwash sampling will 
involve rinsing with 10 ml sterile saline solution for 20 seconds. 
I. Early cardiovascular diseases will be performed by means of an ultrasound machine. 
J. The research team will follow up on you on a yearly basis and some of these test may be 
repeated. The investigators wish to follow you up for your entire life. In the unfortunate event 
that you are deceased during the study period. The study team will review stats SA data and/or 
medical records to ascertain whether the cause of death was due to diabetes or cardiovascular 
diseases.. If you do not wish to be followed up on a yearly basis and your Statistics SA 
and/or medical records not to be accessed in the unfortunate event that you are deceased 
whilst being a participant in the study, you will have an opportunity to request that it be not 
accessed when you sign the consent form. 
K. Radio imaging techniques will be done on consenting subjects. These include (i) ultra sound to 
assess whether you have signs of early cardiovascular diseases, (ii) computed tomography scan 
(CT-scan) to accurately assess the fat content that is dangerous for cardiovascular diseases (iii) 
Dual-energy X-ray absorptiometry (DXA) devices will be used to study the morphology of the 
liver. These radio imaging techniques involve radiation which can be harmful if one is exposed 
excessively. For this study a low dose radiation will be used for acquisition of the images thereby 
minimizing radiation exposure to the participant. If you do not wish to undergo any of these 
radio imaging techniques, you will have an opportunity to decline when you sign the 
consent form. 
L. An eye examination will be done to test your eye vision and any other abnormalities in the 
eye. For this examination, drops placed in your eyes widen (dilate) your pupils to allow the 
doctor to better view inside your eyes. The drops may cause your close vision to blur for a short 
while. 
  
 
 
A slight bruising might occur after blood has been drawn from the arm but this will heal quickly. 
After the administration of the glucose solution, you may feel nauseous and dizzy in which case 
you must notify the medical personnel. A medical nurse or doctor will be present on all occasions. 
You may also learn that you have diabetes, in which case you will be referred to your health care 
giver with the results for further treatment and management. If during the study it is discovered 
that you have changes in your genes that may lead to a serious disease, a genetic counsellor 
at the expense of the principal investigators will counsel you. Radio imaging techniques such 
5.   Are there any risks involved in genetic research? 
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as the CT-scan involves radiation which can be harmful if one is exposed excessively. For this 
study a low dose radiation will be used for acquisition of the images thereby minimizing radiation 
exposure to the participant. 
 
 
 
Your personal results will be made known to you only if they indicate that you may: 
• Have diabetes, thereafter, you will be referred to your local health centre or 
general practitioner for further investigations and treatment. 
• Have a condition or predisposition to developing diabetes that is treatable or avoidable 
e.g. by a lifestyle modification. 
• Need genetic counselling. 
 However, participants with normal results who wish to know their results 
are free to contact the research team and their results will be given upon 
written request. 
 
 
 
The blood samples may be stored indefinitely to accommodate new technologies that may 
develop. In the event that a technology is not available in South Africa to analyse your blood 
sample, your blood specimen may be sent to another country with the technology either now or 
at a later date. However, if your specimen is to be sent to another country, permission to do so 
will be sought from relevant bodies. Your blood specimen will be stored at the Cape Peninsula 
University of Technology. 
 
 
 
Your   blood    will    only    be    used    for    genetic    research    that    is    directly    related    
to Diabetes and cardiovascular diseases. Also if the researchers wish to use your stored blood 
for additional research in this field they will be required to apply for permission to do so from 
the ethics Faculty of Health & Wellness Sciences of the Cape Peninsula University of 
Technology. If you do not wish your blood specimen to be stored after this research 
study is completed you will have an opportunity to request that it be discarded when you 
sign the consent form. 
6.   Are there any benefits to your taking part in this study and will you get told your results? 
7.   How long will your blood be stored and where will it be stored? 
8.   If your blood is to be stored is there a chance that it will be used for other research? 
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Your identity will be recorded once and kept confidential throughout. This is to allow the 
principal investigators to convey information that may be beneficial to you. Access will be limited 
to the principal investigators by assigning a special study code to all your data and blood samples. 
This means that your sample will be identified with a special study code that will remain linked 
to your name and contact details. However, during the entire research study, your blood 
specimens will be anonymised and the research staff won’t be able to associate it with your 
name and contact details. You shall also be supplied this code so that if at any time the 
investigators need to contact you, you may only identify yourself using your special code. Any 
scientific publications, lectures or reports resulting from the study will not identify you. 
Some insurance companies may mistakenly assume that taking part in research indicates a 
higher risk for disease. Thus no information about you or your family will be shared with such 
companies. 
 
 
 
You will not be paid to take part in this study although your out-of-pocket expenses may be 
reimbursed. The expenses that will be covered by the research team are those that include 
transportation to a hospital radiography department should you consent to radio imaging. 
 
 
 
 
 
You should inform your family practitioner or usual doctor that you are taking part in a research 
study. You can contact
9.   How will your confidentiality be protected? 
10. Will you or the researchers benefit financially from this research? 
Important information: In the unlikely event that this research leads to the development of a 
commercial application or patent, you or your family will not receive any profits or royalties, but 
profits will be reinvested into supporting the cause of further research which may bring benefits to 
you or your family and to the community, such as health screening, medical treatment, educational 
promotions, etc. 
11.  Is there anything else you should know or do? 
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  Prof T Matsha at 021 959 6366 or matshat@cput.ac.za, 
If you have any further queries or encounter any problems, you can also contact the Cape Peninsula 
University of Technology Health and Wellness Sciences Research Ethics Committee, 
Chairperson: Prof Engel-hills at 0219596570 or EngelhillsP@cput.ac.za or 
 
You will receive a copy of this information and consent form for your own records if it is requested. 
 
 
 
By signing below, I ………………………………..…………. agree to take part in a research project that 
includes genetic research study entitled (PROGRESSIVE RESEARCH ON RISK FACTORS OF TYPE 
2 DIABETES AND CARDIOVASCULAR DISEASES IN SOUTH AFRICA). 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
• I have received a signed duplicate copy of this consent form for my records. 
 
 
 
 
I agree that my blood or tissue sample can be stored indefinitely after the project is 
completed but that it is anonymised with all possible links to my identity removed, and that 
the researchers may then use it for additional research in this or a related field. Once my 
sample is anonymised, my rights to that sample are waivered. My sample may be shipped 
to another laboratory in SA or abroad to be used in other research projects in this or a 
related field 
12. Declaration by participant 
13. Tick the option you choose: 
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         OR 
 
I agree that my blood or tissue sample can be stored indefinitely, but I can choose 
to request at any time that my stored sample be destroyed. My sample will be identified 
with a special study code that will remain linked to my name and contact details. I have the 
right to receive confirmation that my request has been carried out. 
OR 
Please destroy my blood sample as soon as the current research project has been 
completed. 
 
 
 
I consent that the research team may follow me up for yearly check-up AND in the unfortunate 
event that I am deceased whilst still part of the study, I consent that the team may access Statistics 
SA and/or my medical records to ascertain whether the cause of my death was due to diabetes or 
cardiovascular diseases. 
OR 
 
I do not consent to follow me up for yearly check-up BUT in the unfortunate event that I am 
deceased whilst still part of the study, I consent that the team may access Statistics SA and/or my 
medical records to ascertain whether the cause of my death was due to diabetes or cardiovascular 
diseases. 
OR 
 
I do not consent to follow me up for yearly check-up AND in the unfortunate event that I am 
deceased whilst still part of the study, I do not consent that the team accessing Statistics SA and/or 
my medical records to ascertain whether the cause of my death was due to diabetes or 
cardiovascular diseases. 
 
 
14. Tick the option you choose: 
15. Tick the option you choose: Radio Imaging 
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□ I consent to ultra sound techniques to assess if I have early cardiovascular diseases 
□ I do not consent to ultra sound techniques that assess if I have early cardiovascular diseases 
AND 
 
□ I consent computed  tomography  scan  (CT-scan)  to  accurately  assess  the  fat  content  that  
is dangerous for cardiovascular diseases 
 
□ I do not consent to computed tomography scan (CT-scan) that accurately assess the fat content 
that is dangerous for cardiovascular diseases 
 
AND 
 
□ I consent to Dual-energy X-ray absorptiometry (DXA) used to study body composition. 
□ I do not consent Dual-energy X-ray absorptiometry (DXA) used to study body composition 
 
 
 
 
Signed at (place) .......................................................... on (date) ...................................................... 
 
 
……………………………………………………              ……………………………………………………. 
Signature of participant                                     Signature of witness 
 
 
 
 
Finger print 
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I (name) ………………………………………………… declare that: 
 
• I explained the information in this document to …………………..……………... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
• I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........……………. on (date) …………....………. 2016. 
 
 
....................................................................       .......................................................................... 
          Signature of investigator                      Signature of witness 
 
 
 
I (name) ………………………………………………… declare that: 
 
• I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) 
……………………………. Using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
16. Declaration by investigator 
17. Declaration by Interpreter 
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answered. 
 
 
Signed at (place) ......................…........……………. on (date) …………....………. 2016. 
 
 
........................................................................    .......................................................................... 
         Signature of interpreter                      Signature of witness 
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APPENDIX B 
Ethics clearance certificate 
 
 
 
 
 
 
HEALTH AND WELLNESS SCIENCES RESEARCH ETHICS COMMITTEE (HW-REC) 
Registration Number NHREC: REC- 230408-014     
Africa Symphony Road Bellville 7535 
Tel: +27 21 959 6917 
Email: sethn@cput.ac.za 
                                                                                       18 April 2018 
                                                                                     REC Approval Reference No:                 
                                                                                    CPUT/HW-REC 2016/H30(extension) 
 
Faculty of Health and Wellness Sciences – Biomedical Sciences Dear Ms Mbu 
Re:  APPLICATION TO THE HW-REC FOR ETHICS CLEARANCE 
 
Approval was granted by the Health and Wellness Sciences-REC on 15 September 2016 to Ms 
Desiree Lem Mbu for ethical clearance. This approval is for research activities related to student 
research in the Department of Biomedical Science at this Institution. 
 
TITLE: Expression of circulating microRNA’s (miRNAs) in blood of mixed ancestry 
subjects with glucose intolerance 
 
Supervisor: Professor T Matsha Comment: 
Data collection permission is required and has been obtained. 
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Approval will not extend beyond 19 April 2019. An extension should be applied for 6 weeks 
before this expiry date should data collection and use/analysis of data, information and/or 
samples for this study continue beyond this date. 
 
The investigator(s) should understand the ethical conditions under which they are authorized to 
carry out this study and they should be compliant to these conditions. It is required that the 
investigator(s) complete an annual progress report that should be submitted to the HWS-REC 
in December of that particular year, for the HWS-REC to be kept informed of the progress and 
of any problems you may have encountered. 
 
Kind Regards 
 
 
 
 
Mr. Navindhra Naidoo 
Chairperson – Research Ethics Committee 
Faculty of Health and Wellness Sciences 
 
